0001493152-20-015316.txt : 20200812 0001493152-20-015316.hdr.sgml : 20200812 20200812124317 ACCESSION NUMBER: 0001493152-20-015316 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200812 DATE AS OF CHANGE: 20200812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sintx Technologies, Inc. CENTRAL INDEX KEY: 0001269026 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33624 FILM NUMBER: 201094885 BUSINESS ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 BUSINESS PHONE: 801-839-3516 MAIL ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 FORMER COMPANY: FORMER CONFORMED NAME: AMEDICA Corp DATE OF NAME CHANGE: 20121231 FORMER COMPANY: FORMER CONFORMED NAME: AMEDICA CORP DATE OF NAME CHANGE: 20031104 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-33624

SINTX Technologies, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE		84-1375299
(State or other jurisdiction		(IRS Employer
of incorporation or organization)		Identification No.)

1885 West 2100 South, Salt Lake City, UT		84119
(Address of principal executive offices)		(Zip Code)

(801) 839-3500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock		SINT		The NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days: Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files); Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ]	Smaller reporting company	[X]

		Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

24,544,308 shares of common stock, $0.01 par value, were outstanding at August 10, 2020

SINTX Technologies, Inc.

Table of Contents

Part I. Financial Information
Item 1. Financial Statements
Condensed Consolidated Balance Sheets (unaudited)	3
Condensed Consolidated Statements of Operations (unaudited)	4
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)	5
Condensed Consolidated Statements of Cash Flows (unaudited)	6
Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3. Quantitative and Qualitative Disclosures About Market Risk	23
Item 4. Controls and Procedures	23
Part II. Other Information
Item 1. Legal Proceedings	24
Item 1A. Risk Factors	24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3. Defaults Upon Senior Securities	24
Item 4. Mine Safety Disclosures	24
Item 5. Other Information	24
Item 6. Exhibits	25
Signatures	26

SINTX Technologies, Inc.

Condensed Consolidated Balance Sheets - Unaudited

(in thousands, except share and per share data)

	June 30, 2020			December 31, 2019

Assets
Current assets:
Cash and cash equivalents	$	18,125		$	1,787
Account and other receivables		60			136
Prepaid expenses and other current assets		403			310
Inventories, net		137			106
Notes receivable, current portion		2,119			1,724
Total current assets		20,844			4,063

Inventories, net		522			533
Property and equipment, net		232			190
Intangible assets, net		39			41
Long-term note receivable, net of current portion		778			1,944
Operating lease right-of-use-asset		2,135			2,341
Other long-term assets		35			35
Total assets	$	24,585		$	9,147

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	96		$	191
Accrued liabilities		1,281			1,266
Derivative liabilities		1,503			220
Current portion of operating lease liability		383			360
Current portion of debt		180			6
Other current liabilities		23			23
Total current liabilities		3,466			2,066

Operating lease liability, net of current portion		1,682			1,867
Long term debt		241			12
Total liabilities		5,389			3,945

Commitments and contingencies

Stockholders’ Equity:
Convertible preferred stock Series B, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 126 shares and 249 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively.		-			-
Convertible preferred stock Series C, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 53 shares and 0 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively.		-			-
Common stock, $0.01 par value, 250,000,000 shares authorized; 19,430,913 shares, and 2,434,009 shares issued and outstanding at June 30, 2020 and December 31, 2019.		194			24
Additional paid-in capital		255,939			239,256
Accumulated deficit		(236,937	)		(234,078	)
Total stockholders’ equity		19,196			5,202
Total liabilities and stockholders’ equity	$	24,585		$	9,147

The condensed consolidated balance sheet as of December 31, 2019, has been prepared using information from the audited consolidated balance sheet as of that date.

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Operations - Unaudited

(in thousands, except share and per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Product revenue	$	204		$	167		$	411		$	264
Costs of revenue		163			133			329			212
Gross profit		41			34			82			52
Operating expenses:
Research and development		1,068			836			2,061			1,554
General and administrative		826			615			1,591			1,586
Sales and marketing		131			105			268			164
Total operating expenses		2,025			1,556			3,920			3,304
Loss from operations		(1,984	)		(1,522	)		(3,838	)		(3,252	)
Other income (expenses):
Interest expense		(1	)		(2	)		(1	)		(2	)
Interest income		85			115			189			237
Change in fair value of derivative liabilities		(2,128	)		631			2,037			610
Offering costs		-			-			(1,246	)		-
Other income, net		-			48			-			48
Total other income (expense), net		(2,044	)		792			979			893
Net loss before income taxes		(4,028	)		(730	)		(2,859	)		(2,359	)
Provision for income taxes		-			-			-			-
Net loss		(4,028	)		(730	)		(2,859	)		(2,359	)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock		(207	)		(2,358	)		(9,491	)		(2,358	)
Net loss attributable to common stockholders	$	(4,235	)	$	(3,088	)	$	(12,350	)	$	(4,717	)

Net loss per share – basic and diluted
Basic – net loss	$	(0.33	)	$	(0.78	)	$	(0.32	)	$	(2.84	)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock		(0.02	)		(2.53	)		(1.05	)		(2.84	)
Basic – attributable to common stockholders	$	(0.35	)	$	(3.31	)	$	(1.37	)	$	(5.68	)

Diluted –net loss	$	(0.33	)	$	(1.46	)	$	(0.45	)	$	(3.58	)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock		(0.02	)		(2.53	)		(0.84	)		(2.84	)
Diluted – attributable to common stockholders	$	(0.35	)	$	(3.99	)	$	(1.29	)	$	(6.42	)
Weighted average common shares outstanding:
Basic		12,120,420			931,859			9,070,655			829,724
Diluted		12,120,420			931,859			11,314,252			829,724

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Stockholders’ Equity - Unaudited

(in thousands, except share and per share data)

	Preferred B Stock					Preferred C Stock				Common Stock				Paid-In			Accumulated			Total
	Shares			Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of December 31, 2018		4,074		$	-		-	$	-		726,455	$	7	$	237,673		$	(229,281	)	$	8,399
Common stock issued from exercise of warrants for cash		-			-		-		-		500		-		1			-			1
Common stock issued due to conversion of preferred stock		(3,337	)		-		-		-		983,528		10		(10	)		-			-
Stock based compensation		-			-		-		-		-		-		1			-			1
Common stock issued for cash, net of fees		-			-		-		-		144,415		1		396			-			397
Removal of derivative liability upon exercise of warrant		-			-		-		-		-		-		1			-			1
Net loss		-			-		-		-		-		-		-			(2,359	)		(2,359	)
Balance as of June 30, 2019		737		$	-		-	$	-		1,854,898	$	18	$	238,062		$	(231,640	)	$	6,440

	Preferred B Stock					Preferred C Stock					Common Stock				Paid-In			Accumulated			Total
	Shares			Amount		Shares			Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of December 31, 2019		249		$	-		-		$	-		2,434,009	$	24	$	239,256		$	(234,078	)	$	5,202
Common stock issued for cash, net of fees		-			-		-			-		6,454,381		65		9,583			-			9,648
Extinguishment of derivative liability upon exercise of warrant		-			-		-			-		-		-		3,008			-			3,008
Issuance of common stock from the exercise of warrants for cash		-			-		-			-		611,968		6		911			-			917
Issuance of common stock from the cashless exercise of warrants		-			-		-			-		3,502,645		35		(35	)		-			-
Preferred stock issued for cash, net of fees		-			-		9,440			-		-		-		3,112			-			3,112
Common stock issued on conversion of preferred stock		(123	)		-		(9,387	)		-		6,427,910		64		(64	)		-			-
Issuance of agent warrants		-			-		-			-		-		-		168			-			168
Beneficial conversion feature on issuance of convertible preferred stock		-			-		-			-		-		-		3,111			-			3,111
Deemed dividend related to the issuance of preferred stock		-			-		-			-		-		-		(3,111	)		-			(3,111	)
Accretion of convertible preferred stock discount		-			-		-			-		-		-		6,380			-			6,380
Deemed dividend related to the conversion of preferred stock		-			-		-			-		-		-		(6,380	)		-			(6,380	)
Net loss		-			-		-			-		-		-		-			(2,859	)		(2,859	)
Balance as of June 30, 2020		126		$	-		53		$	-		19,430,913	$	194	$	255,939		$	(236,937	)	$	19,196

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Cash Flows - Unaudited

(in thousands)

	Six Months Ended June 30,
	2020			2019
Cash Flow From Operating Activities
Net loss	$	(2,859	)	$	(2,359	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		34			52
Amortization of right of use asset		206			171
Amortization of intangible assets		2			2
Non-cash interest income		(172	)		(237	)
Change in fair value of derivative liabilities		(2,037	)		(610	)
Offering Costs		325			-
Bad debt expense		-			9
Changes in operating assets and liabilities:
Trade accounts receivable		76			79
Prepaid expenses and other current assets		(251	)		(63	)
Inventories		(20	)		(5	)
Accounts payable and accrued liabilities		(79	)		(19	)
Payments on operating lease liability		(163	)		(354	)
Net cash used in operating activities		(4,938	)		(3,333	)
Cash Flows From Investing Activities
Purchase of property and equipment		(77	)		(15	)
Proceeds from notes receivable, net of imputed interest		944			695
Net cash provided by investing activities		867			680
Cash Flows From Financing Activities
Proceeds from issuance of warrant derivative liabilities		6,328			-
Proceeds from issuance of common stock, net of fees		9,648			397
Proceeds from issuance of preferred stock, net of fees		3,112			-
Proceeds from issuance of common stock in connection with exercise of warrants		917			1
Proceeds from issuance of debt		406			-
Principal payments on debt		(2	)		-
Net cash provided by financing activities		20,409			398
Net increase (decrease) in cash and cash equivalents		16,338			(2,255	)
Cash and cash equivalents at beginning of period		1,787			5,447
Cash and cash equivalents at end of period	$	18,125		$	3,192

Noncash Investing and Financing Activities
Reduction of derivative liability due to exercise of warrants	$	3,008		$	1
Change in par value due to conversion of preferred stock to common stock		64			-
Issuance of Common Stock for the Cashless Exercise of Warrants		35
Right-of-use assets and assumption of operating lease liability		-			2,704
Supplemental Cash Flow Information
Cash paid for interest	$	1		$	2

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Summary of Significant Accounting Policies

Organization

SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company’s products are primarily sold in the United States.

Reverse Stock Split

On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed financial statements have been adjusted retroactively to reflect the reverse stock split.

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. During the three months ended June 30, 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated.

SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 26, 2020. The results of operations for the six months ended June 30, 2020, are not necessarily indicative of the results to be expected for the year ending December 31, 2020. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of June 30, 2020, the most significant estimates relate to inventory, long-lived and intangible assets, the liability for preferred stock and common stock warrants, and the derivative liabilities.

Liquidity and Capital Resources

The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.

For the six months ended June 30, 2020 and 2019, the Company incurred a net loss of $2.9 million and $2.4 million, respectively, and used cash in operations of $4.9 million and $3.3 million, respectively. The Company had an accumulated deficit of $237 million and $234 million as of June 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.

The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9.6 million, before considering issuance costs of approximately $0.8 million (see Note 8).

During the year ended December 31, 2019, the Company entered into an at-the-market (ATM) equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million. During the six month period ending June 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of June 30, 2020, no funding capacity is available under the ATM. (see Note 8).

On October 1, 2018, the Company sold the retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable payable over a 36-month term. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable to occur October 1, 2021. The Company expects cash flows of approximately $3.1 million for the remaining sixteen months.

Management has concluded that together with its existing capital resources and payments on the note receivable from the sale of the Spine business will be sufficient to fund operations for at least the next 12 months, or through August 2021. In the financial statements for the year ended December 31, 2019, the Company concluded substantial doubt existed for the Company to continue as a going concern. Beginning with the period ended March 31, 2020, the Company’s position changed as a result of the capital raises outlined in Note 8.

Risks Related to COVID-19 Pandemic

The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.

New Accounting Pronouncements Not Yet Adopted

The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

2. Basic and Diluted Net Income (Loss) per Common Share

Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. For the three months ended June 30, 2020, there is no difference in the number of shares and net loss used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive. The Company had potentially dilutive securities, totaling approximately 1.3 million and 0.6 million as of June 30, 2020 and 2019, respectively.

Below are basic and diluted loss per share data for the six months ended June 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(2,859	)	$	(2,191	)	$	(5,050	)
Deemed dividend and accretion of a discount		(9,491	)		-			(9,491	)
Net loss attributable to common stockholders	$	(12,350	)	$	(2,191	)	$	(14,541	)

Denominator:
Number of shares used in per common share calculations:		9,070,655			2,243,597			11,314,252

Net income (loss) per common share:
Net loss	$	(0.32	)	$	(0.13	)	$	(0.45	)
Deemed dividend and accretion of a discount		(1.05	)		0.21			(0.84	)
Net income (loss) attributable to common stockholders	$	(1.37	)	$	0.08		$	(1.29	)

Below are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(730	)	$	(632	)	$	(1,362	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(3,088	)	$	(632	)	$	(3,720	)

Denominator:
Number of shares used in per common share calculations:		931,859			-			931,859

Net loss per common share:
Net loss	$	(0.78	)	$	(0.68	)	$	(1.46	)
Deemed dividend and accretion of a discount		(2.53	)		-			(2.53	)
Net loss attributable to common stockholders	$	(3.31	)	$	(0.68	)	$	(3.99	)

Below are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(2,359	)	$	(609	)	$	(2,968	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(4,717	)	$	(609	)	$	(5,326	)

Denominator:
Number of shares used in per common share calculations:		829,724			-			829,724

Net loss per common share:
Net loss	$	(2.84	)	$	(0.74	)	$	(3.58	)
Deemed dividend and accretion of a discount		(2.84	)		-			(2.84	)
Net loss attributable to common stockholders	$	(5.68	)	$	(0.74	)	$	(6.42	)

3. Inventories

Inventories consisted of the following (in thousands):

	June 30, 2020		December 31, 2019
Raw materials	$	522	$	533
WIP		127		106
Finished Goods		10		-
	$	659	$	639

As of June 30, 2020, inventories totaling approximately $0.1 million and $0.5 million were classified as current and long-term, respectively. Inventories classified as current represent the carrying value of inventories as of June 30, 2020, that management estimates will be sold by June 30, 2021.

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2020			December 31, 2019
Trademarks	$	50		$	50
Less: accumulated amortization		(11	)		(9	)
	$	39		$	41

Amortization expense for the six months ended June 30, 2020, was approximately $2.0 thousand. Amortization expense for the six months ended June 30, 2019, was approximately $2.0 thousand.

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

	Level 1 -	quoted market prices for identical assets or liabilities in active markets.

	Level 2 -	observable prices that are based on inputs not quoted on active markets but corroborated by market data.

	Level 3 -	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of June 30, 2020 and December 31, 2019. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2020 and December 31, 2019 (in thousands):

	Fair Value Measurements as of June 30, 2020
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,503	$	1,503

	Fair Value Measurements as of December 31, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	220	$	220

The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the six months ended June 30, 2020 and 2019 (in thousands).

	Common Stock Warrants
Balance as of December 31, 2018	$	(1,566	)
Change in fair value		610
Balance as of June 30, 2019	$	(956	)

Balance as of December 31, 2019	$	(220	)
Issuance of derivatives		(6,328	)
Change in fair value		2,037
Exercise of warrants		3,008
Balance as of June 30, 2020	$	(1,503	)

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of June 30, 2020, and December 31, 2019, the derivative liability was calculated using the Monte Carlo Simulation valuation.

The assumptions used in estimating the common stock warrant liability as of June 30, 2020 and December 31, 2019 were as follows:

	June 30, 2020			December 31, 2019
Weighted-average risk-free interest rate		0.18%-0.36	%		1.62	%
Weighted-average expected life (in years)		2.86-4.80			3.4
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		68.51%-77.50	%		64	%

Other Financial Instruments

The Company’s recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of debt approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2020		December 31, 2019
Payroll and related expense	$	603	$	589
Resterilization and repackaging costs		332		392
Other		346		285
	$	1,281	$	1,266

7. Debt

Equipment Loan

In September 2019, the Company entered into a debt arrangement with a finance company to purchase equipment. The debt balance as of June 30, 2020, totaled $15 thousand. The debt incurs interest at 12%, is collateralized by the equipment and is payable in monthly payments of $1,000 (including interest) over 36 months.

PPP Loan

On April 28, 2020, the Company received funding under a Paycheck Protection Program (“PPP”) loan (the “PPP Loan”) from First State Community Bank (the “Lender”). The principal amount of the PPP Loan is $0.391 million. The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (the “SBA”). The PPP Loan has a two-year term, maturing on April 28, 2022. The term may be extended to five-years if the Lender and we agree to do so. The interest rate on the PPP Loan is 1.0% per annum. Principal and interest are payable in 18 monthly installments, beginning on November 28, 2020, until maturity with respect to any portion of the PPP Loan which is not forgiven as described below. The Company did not provide any collateral or guarantees for the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The PPP Loan provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company is permitted to prepay or partially prepay the PPP Loan at any time with no prepayment penalties. The PPP Loan may be partially or fully forgiven if the Company complies with the provisions of the CARES Act, including the use of PPP Loan proceeds for payroll costs, rent, utilities and other expenses, provided that such amounts are incurred during a 24-week period that commenced on April 28, 2020 and at least 60% of any forgiven amount has been used for covered payroll costs as defined by the CARES Act. Any forgiveness of the PPP Loan will be subject to approval by the SBA and the Lender and will require the Company to apply for such treatment in the future.

Other Debt

The Company has other debt totaling $15 thousand as of June 30, 2020 (none at December 31, 2019).

8. Equity

2020 Rights Offering

During February 2020, the Company closed on a rights offering capital raise wherein the Company’s holders of common stock, Series C Preferred Stock, and certain outstanding warrants on the date of record, obtained, at no charge, non-transferable subscription rights to purchase units (“Units”). Each Unit consisted of one share of Series C Convertible Preferred Stock (“Preferred Stock”) and 675 warrants to purchase common stock (“Warrants”). Each Unit sold for $1,000. Each share of the Preferred Stock is convertible, at the Company’s option at any time on or after the first anniversary of the expiration of the rights offering or at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the Conversion Price ($1.4814 per share). Each Warrant is exercisable for one share of our common stock at an exercise price of $1.50 per share from the date of issuance through its expiration five years from the date of issuance. The Warrants also contain a cashless exercise provision that allows the holder to receive 70% of the common stock otherwise available under the warrant to the holder electing the cashless exercise provision. The Company issued 9,440 Units, which includes 6,372,000 Warrants exercisable into shares of our common stock and preferred shares that are convertible into 6,372,350 shares of Common Stock, for gross proceeds of $9.4 million.

The Company raised $9.4 million, before consideration of issuance costs, associated with the issuance of the Units, with $3.1 million allocated to the preferred stock (with no issuance costs allocated to the preferred stock) and $5.1 million, net of issuance costs of approximately $1.2 million, allocated to the warrants. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed approximately all $1.2 million of the issuance costs.

During the six months ended June 30, 2020, Series B Convertible Preferred stockholders of the Company converted 123 shares of Series B Convertible Preferred Stock into 91,333 shares of common stock, and Series C Convertible Preferred stockholders of the Company converted 9,387 shares of Series C Convertible Preferred Stock into 6,336,577 shares of common stock.

Also, during the six months ended June 30, 2020, holders of Warrants electing to use the cashless exercise option exercised 5,003,775 warrants, which resulted in the issuance of 3,502,645 shares of common stock. During the same period of time, holders of Warrants electing to exercise warrants for cash exercised 611,968 warrants, which resulted in the issuance of 611,968 shares of common stock, and the receipt of $0.9 million of cash.

2020 Registered Direct Offerings

During June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9.6 million, before considering issuance costs of approximately $0.8 million. On June 23, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 3,700,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $1.50 per share for aggregate gross proceeds to the Company of approximately $5.5 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. Following the initial registered direct offering, on June 26, 2020, the Company entered into another Share Purchase Agreement with certain institutional purchasers pursuant to which the Company offered to the purchasers, in a registered direct offering, an aggregate of 2,400,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $1.72 per share for aggregate gross proceeds to the Company of approximately $4.1 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. See Note 14, Subsequent Events, for a description of the third and fourth registered direct offerings executed subsequent to June 30, 2020.

2019 ATM Stock Offerings

On June 4, 2019, the Company entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of its common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). On September 12, 2019, the Company entered into an amendment to the Distribution Agreement with Maxim, which increased the maximum aggregate offering price of the shares of the Company’s common stock from $1.6 million to $2.5 million. Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on the Company’s instructions. The Company has no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $2.5 million, (ii) the termination of the Distribution Agreement by either Maxim or the Company upon the provision of fifteen (15) days written notice, or (iii) September 12, 2020. The Company agrees to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the year ended December 31, 2019, the Company raised approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million, through the issuance of 527,896 shares of common stock under the Distribution Agreement with Maxim. During the six month period ending June 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million before deducting issuance fees of approximately $0.034 million. As of June 30, 2020, no funding capacity is available under the ATM.

9. Stock-Based Compensation

The Company recorded no outstanding stock option activity for the six months ended June 30, 2020. As of June 30, 2020, the Company had 377 options exercisable and outstanding with a weighted average exercisable price of approximately $7,447. The weighted average remaining contractual life was 4.8 years as of June 30, 2020. The options hold no intrinsic value. Total stock-based compensation expense included in the condensed consolidated statements of operations was $0 thousand for the six months ended June 30, 2020. There was no significant unrecognized stock-based compensation as of June 30, 2020.

10. Commitments and Contingencies

The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock options.

From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s financial position, operating results or cash flows.

11. Note Receivable

On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021. The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization. As of June 30, 2020, the net carrying value of the note receivable was approximately $2.9 million, with expected cash proceeds of $3.1 million.

12. Discontinued Operations

The Company and CTL Medical entered in an asset purchase agreement on October 1, 2018, whereby CTL Medical agreed to acquire all of the Company’s commercial spine business for total consideration of $8.5 million, which includes a $6.0 million (including interest) note receivable and CTL Medical’s assumption of the Company’s $2.5 million related party note payable to North Stadium. As a result of the closing, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. The Company has agreed to pay the cost, if any, to re-sterilize and re-package select silicon nitride spinal inventories sold to CTL Medical if the sterilization date expires prior to CTL Medical selling the inventories to a third-party customer. This agreement extends for a total of 24 months, ending on September 30, 2020. The Company estimates the sterilization and repackaging cost to approximate $0.3 million at June 30, 2020. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company in Salt Lake City. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.

13. Leases

The Company leases office, warehouse and manufacturing space under a single operating lease. On June 7, 2019, the lease was amended to extend the rental period through 2024 and reduce the amount of space leased from 54,428 square feet to 29,732 square feet. The new rent was effective January 1, 2020. The amended lease has two five-year extension options. As of June 30, 2020, the operating lease right-of-use asset totaled approximately $2.1 million and the operating lease liability totaled approximately $2.1 million. Non-cash operating lease expense during the six months ended June 30, 2020, totaled approximately $0.2 million. As of June 30, 2020, the weighted-average discount rate for the Company’s operating lease was 6.5%.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.

Operating lease future minimum payments together with the present values as of June 30, 2020, are summarized as follows:

Years Ending December 31,	June 30, 2020
2020	$	249
2021		513
2022		528
2023		544
2024		561
Thereafter		-
Total future minimum lease payments		2,395
Less amounts representing interests		(330	)
Present value of lease liability		2,065

Current-portion of operating lease liability		383
Long-term portion operating lease liability	$	1,682

14. Subsequent Events

On July 9, 2020, the Company received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it has regained compliance with NASDAQ’s minimum bid price requirements for continued listing on the Nasdaq Capital Market. The letter noted that as a result of the closing bid price of the Company’s common stock having been at $1.00 per share or greater for at least ten consecutive business days, from June 22, 2020 to July 8, 2020, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.

On July 16, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 1,500,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $2.00 per share for aggregate gross proceeds to the Company of $3.0 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.

On August 7, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 3,415,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $2.40 per share for aggregate gross proceeds to the Company of $8.2 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements for the year ended December 31, 2019 and the notes thereto, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed separately with the U.S. Securities and Exchange Commission. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, expectations, intentions and projections that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019, and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q and in other filings with the Securities and Exchange Commission we may make from time-to-time.

Overview

We are an advanced materials company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. We believe that silicon nitride has a superb combination of properties that make it ideally suited for long-term human implantation. Other biomaterials are based on bone grafts, metal alloys, and polymers, all of which have well-known practical limitations and disadvantages. In contrast, silicon nitride has a legacy of success in the most demanding and extreme industrial environments. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial and viral infection, ease of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance, among other advantages, all of which claims are validated in our large and growing inventory of peer-reviewed, published literature reports.

We recently received positive testing results from an independent study that demonstrate the potential anti-viral properties of our silicon nitride. The results suggest that silicon nitride may be useful in the reduction of the spread of COVID-19. The study results demonstrated that our unique grade of silicon nitride inactivates the SARS-CoV-2 virus within a minute after exposure and has the potential to decrease the risk of viral disease spread on surfaces. Studies have shown that coronavirus spreads between humans when an infected person coughs or sneezes. Also, the virus can remain active on a variety of commonly touched surfaces for hours to days. We believe that by incorporating our unique composition of silicon nitride into products such as face masks, and personal protective equipment, it is possible to manufacture surfaces that inactivate viral particles, thereby limiting the spread of the disease. We envision incorporating our silicon nitride into high-contact surfaces such as medical equipment, screens, countertops, and doorknobs in locations where viral persistence is a concern, such as homes, casinos, and cruise ships. We believe this anti-viral discovery will open many new opportunities for us. In composites, coatings, and mixtures, silicon nitride has maintained its antibacterial and osteogenic properties, even at small fractions. We believe that incorporating our material into a variety of commonly-touched surfaces may discourage viral spread, and contribute to global health by reducing the risk of disease. We believe that our versatile silicon nitride manufacturing expertise positions us favorably to introduce new and innovative devices in the medical and non-medical fields.

We also believe that we are the first and only company to commercialize silicon nitride medical implants. Prior to October 1, 2018, we designed, manufactured and commercialized silicon nitride products for our own behalf in the spine implant market. Over 35,000 of our spinal implants manufactured with silicon nitride have been implanted into patients, with an excellent safety record. On October 1, 2018, we sold our spine implant business to CTL Medical and now manufacture spine implants made with silicon nitride for CTL Medical. Prior to selling our spine implant business to CTL Medical, we had received 510(k) regulatory clearance in the United States, a CE mark in Europe, ANVISA approval in Brazil, and ARTG and Prostheses approvals in Australia for a number of silicon nitride spine implant products designed for spinal fusion surgery. Spine implant products manufactured by us from silicon nitride are currently marketed and sold by CTL Medical under the Valeo® brand to surgeons and hospitals in the United States and to selected markets in Europe and South America. These implants are designed for use in cervical (neck) and thoracolumbar (lower back) spine surgery. We are collaborating with CTL Medical to establish commercial partners in other parts of the world and also working with other partners to obtain regulatory approval for silicon nitride implants in Japan.

The sale of our spine implant business to CTL Medical enables us to now focus on our core competencies. These include research and development of silicon nitride and the design and manufacture of medical and nonmedical products manufactured from silicon nitride and other ceramic materials for our own account and in collaboration with other medical device manufacturers. We are targeting original equipment manufacturer (“OEM”) – including CTL Medical - and private label partnerships in order to accelerate adoption of silicon nitride in future markets such as coating products with silicon nitride, hip and knee replacements, dental and maxillofacial implants, extremities, trauma, bearings, automotive and aerospace components, and cutting tools. Existing biomaterials, based on plastics, metals, and bone grafts have well-recognized limitations that we believe are addressed by silicon nitride.

We believe that silicon nitride addresses many of the biomaterial-related limitations in medical related fields such as hip and knee replacements, dental and maxillofacial implants, sports medicine, extremities, and trauma surgery. We further believe that the inherent material properties of silicon nitride, and the ability to formulate the material in a variety of compositions, combined with precise control of the surface properties of the material, opens up a number of commercial opportunities across orthopedic surgery, neurological surgery, maxillofacial surgery, other medical disciplines, as well as commodity items such as industrial fasteners, bushings, and valves to addressing more complex demands of hypersonic missile radomes, aerospace, air-conditioning systems, beverage dispensers, touch-screen glass, and agribusiness fungicides. In the second quarter, the Company shipped three prototype orders of industrial products totaling $7 thousand and these are believed to be the first such shipments in the Company’s history.

Components of our Results of Operations

We manage our business within one reportable segment, which is consistent with how our management reviews our business, makes investment and resource allocation decisions and assesses operating performance.

Product Revenue

We derive our product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders to CTL Medical, with whom we entered into a 10-year exclusive sales agreement in October 2018. We are currently pursuing other sales opportunities for silicon nitride products outside the spinal fusion application and have shipped new orders for these products. We generally recognize revenue from sales where control transfers at a point in time as the title and risk of loss passes to the customer, which is at the time the product is shipped. In general, our customer does not have rights of return or exchange.

Prior to the occurrence of the COVID-19 pandemic, we believed that our product revenue would increase as CTL Medical increased sales of silicon nitride spinal fusion products, as we secured other opportunities to manufacture third party products with silicon nitride, and as we continued to introduce new products into the market. We now expect COVID-19 to adversely impact product revenue from silicon nitride spinal fusion products in the second half of 2020, and potentially longer.

Cost of Revenue

The expenses that are included in cost of revenue include all in-house manufacturing costs for the products we manufacture.

Gross Profit

Our gross profit measures our product revenue relative to our cost of revenue. We expect our gross profit percentage to decrease as we expand the penetration of our silicon nitride technology platform through OEM and private label partnerships, which offer additional avenues for the adoption of silicon nitride. Prior to the sale of our retail spine business, our revenues and gross profits were based on our retail sales. With the focus on OEM and private label partnerships, the margins are lower, thus causing the decrease in our gross profit percentage.

Research and Development Expenses

Our research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, clinical trials, test-part manufacturing, testing, developing and validating the manufacturing process, manufacturing, facility and regulatory-related costs. Research and development expenses also include employee compensation, employee and non-employee stock-based compensation, supplies and materials, consultant services, and travel and facilities expenses related to research and development activities.

We expect to incur additional research and development costs as we continue to develop new spinal fusion products, product candidates for total joint replacements, dental applications, and other products which may increase our total research and development expenses.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation for certain members of our executive team and other personnel employed in finance, compliance, administrative, information technology, customer service, executive and human resource departments. General and administrative expenses also include other expenses not part of the other cost categories mentioned above, including facility expenses and professional fees for accounting and legal services.

RESULTS OF OPERATIONS

The following is a tabular presentation of our unaudited condensed consolidated operating results for the three months ended June 30, 2020 and 2019 (in thousands):

	Three Months Ended June 30,						$			%			Six Months Ended June 30,						$			%
	2020			2019			Change			Change			2020			2019			Change			Change
Product revenue	$	204		$	167		$	37			22	%	$	411		$	264		$	147			56	%
Cost of revenue		163			133			30			23	%		329			212			117			55	%
Gross profit		41			34			7			21	%		82			52			30			58	%
Gross profit %		20	%		20	%		0	%		0	%		20	%		20	%		0	%		0	%

Operating expenses:
Research and development		1,068			836			232			28	%		2,061			1,554			507			33	%
General and administrative		826			615			211			34	%		1,591			1,586			5			0	%
Sales and marketing		131			105			26			25	%		268			164			104			63	%
Total operating expenses		2,025			1,556			469			30	%		3,920			3,304			616			19	%
Loss from operations		(1,984	)		(1,522	)		(462	)		30	%		(3,838	)		(3,252	)		(586	)		18	%
Other income (expense)		(2,044	)		792			(2,836	)		-358	%		979			893			86			10	%
Net loss before taxes		(4,028	)		(730	)		(3,298	)		452	%		(2,859	)		(2,359	)		(500	)		21	%
Provision for income taxes		-			-			-						-			-			-
Net loss	$	(4,028	)	$	(730	)	$	(3,298	)		452	%	$	(2,859	)	$	(2,359	)	$	(500	)		21	%

Product Revenue

For the three months ended June 30, 2020, total product revenue was $0.204 million as compared to $0.167 million in the same period 2019, an increase of $0.037 million, or 22%. This increase was due to an increase in orders from CTL Amedica and to several non-medical orders.

For the six months ended June 30, 2020, total product revenue was $0.411 million as compared to $0.264 million in the same period 2019, an increase of $0.147 million, or 56%. This increase was primarily due to an increase in orders from CTL Amedica and to some non-medical orders.

Cost of Revenue and Gross Profit

For the three months ended June 30, 2020, our cost of revenue increased $0.030 million, or 23%, as compared to the same period in 2019. Gross profit increased $0.007 million or 21%. Both increases are primarily due to increase in product revenue, and the associated increase in costs of goods sold. Gross profit margin percentage totaled 20% for each period.

For the six months ended June 30, 2020, our cost of revenue increased $0.117 million, or 55%, as compared to the same period in 2019. Gross profit increased $0.030 million or 58%. Both increases correspond with the increase in product revenue, and the associated increase in costs of goods sold. Gross profit margin percentage totaled 20% for each period.

Research and Development Expenses

For the three months ended June 30, 2020, research and development expenses increased $0.2 million, or 28%, as compared to the same period in 2019. This increase was primarily attributable to an overall increase in R&D personnel to support the Company’s strategic objective of developing new technologies and related products.

For the six months ended June 30, 2020, research and development expenses increased $0.5 million, or 33%, as compared to the same period in 2019. This increase was primarily attributable to an increase in R&D wages for new personnel and outside research activities related to testing the anti-viral properties of silicon nitride to support the Company’s strategic objective of developing new technologies and related products.

General and Administrative Expenses

For the three months ended June 30, 2020, general and administrative expenses increased $0.2 million, or 34%, as compared to the same period in 2019. This increase is primarily due to the increase in franchise taxes, reserve increases, and a reduction of bad debt expenses that took place in the prior year.

For the six months ended June 30, 2020, general and administrative expenses had approximately no change, as compared to the same period in 2019.

Sales and Marketing Expenses

For the three months ended June 30, 2020, sales and marketing expenses increased $0.03 million, or 25%, as compared to the same period in 2019. This increase was primarily attributable to an increase in marketing activities to generate interest in and exposure to the Company’s potential new product lines.

For the six months ended June 30, 2020, sales and marketing expenses increased $0.1 million, or 63%, as compared to the same period in 2019. This increase was primarily attributable to an increase in marketing activities to generate interest in and exposure to the Company’s potential new product lines.

Other Income, Net

For the three months ended June 30, 2020, other income decreased $2.8 million, or 358%, as compared to the same period in 2019. This decrease was primarily due to the change in the fair value of the derivative liabilities in the amount of $2.8 million.

For the six months ended June 30, 2020, other income increased $0.1 million, or 10%, as compared to the same period in 2019. This increase was primarily due to the change in the fair value of the derivative liabilities in the amount of $1.4 million offset by the decrease in income due to offering costs of $1.2 million associated with the February 2020 rights offering and interest income of $0.1 million.

Liquidity and Capital Resources

For the six months ended June 30, 2020 and 2019, the Company incurred a net loss of $2.9 million and a net loss of $2.4 million, respectively, and used cash in operations of $4.9 million and $3.3 million, respectively. The Company had an accumulated deficit of $237 million and $234 million as of June 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.

The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications. For instance, we recently received positive testing results from an independent study that demonstrate the potential anti-viral properties of our silicon nitride. We believe that we may be able to apply our silicon nitride powder to personal protection products, such as face masks, gowns and gloves, resulting in inactivation of viruses that come into contact with the items.

The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. Additionally, during June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9,600,000, which excludes underwriting discounts and commissions and offering expenses payable by the Company.

During the year ended December 31, 2019, the Company entered into an ATM equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before considering issuance costs. During the six month period ending June 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million before considering issuance costs. As a result of the sales during the first half of 2020 there are no longer any funds available to the Company under the ATM.

Risks Related to COVID-19 Pandemic

Cash Flows

The following table summarizes, for the periods indicated, cash flows from operating, investing and financing activities (in thousands) – unaudited:

	Six Months Ended June 30,
	2020			2019
Net cash used in operating activities	$	(4,938	)	$	(3,333	)
Net cash provided by investing activities		867			680
Net cash provided by financing activities		20,409			398
Net cash provided (used)	$	16,338		$	(2,255	)

Net Cash Used in Operating Activities

Net cash used in operating activities was $4.9 million during the six months ended June 30, 2020, compared to $3.3 million used during the six months ended June 30, 2019, an increase of $1.6 million. The increase in the net loss from operations, and related non-cash add backs to the net loss, was $1.5 million from 2020 when compared to 2019. The increase in cash used for operating activities during 2020 was primarily due to the $1.5 million mentioned above plus changes in the movement of working capital items during 2020 as compared to the same period in 2019 as follows: a $0.2 million increase in cash used in prepaid expenses, and a $0.1 million increase in cash used in accounts payable, offset by a $0.2 million decrease in cash payments on operation lease liability.

Net Cash Provided by Investing Activities

Net cash provided by investing activities increased by $0.2 million during the six months ended June 30, 2020, as compared to the same period in 2019. This increase was primarily due to an increase in proceeds from notes receivable.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was $20.4 million during the six months ended June 30, 2020, compared to net cash provided by financing activities of $0.4 million during the same period in 2019. The $20.0 million increase was primarily attributable an increase in proceeds from rights offerings of $9.4 million, an increase in proceeds from issuance of common stock in the amount of $9.3 million, an increase in proceeds of $0.9 million from warrants exercised for cash, and $0.4 million increase from the issuance of debt.

Indebtedness

Equipment Loan

In September 2019, the Company entered into a debt arrangement with a finance company to purchase equipment. The debt balance as of June 30, 2020, totaled $0.02 million. The debt incurs interest at 12%, is collateralized by the equipment and is payable in monthly payments of $1.0 thousand (including interest) over 36 months.

PPP Loan

On April 28, 2020, the Company received funding under a Paycheck Protection Program (“PPP”) loan (the “PPP Loan”) from First State Community Bank (the “Lender”). The principal amount of the PPP Loan is $0.391 million. The PPP Loan has a two-year term, maturing on April 28, 2022. The term may be extended to five-years if the Lender and we agree to do so. The interest rate on the PPP Loan is 1.0% per annum. Principal and interest are payable in 18 monthly installments, beginning on November 28, 2020, until maturity with respect to any portion of the PPP Loan which is not forgiven as described below. The PPP Loan may be partially or fully forgiven if the Company complies with the provisions of the CARES Act, including the use of PPP Loan proceeds for payroll costs, rent, utilities and other expenses, provided that such amounts are incurred during a 24-week period that commenced on April 28, 2020 and at least 60% of any forgiven amount has been used for covered payroll costs as defined by the CARES Act. Any forgiveness of the PPP Loan will be subject to approval by the SBA and the Lender and will require the Company to apply for such treatment in the future.

Other Debt

The Company has other debt totaling $15 thousand as of June 30, 2020 (none at December 31, 2019).

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Estimates

A summary of our significant accounting policies and estimates is discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no material changes to those policies for the six months ended June 30, 2020. The preparation of the condensed financial statements in accordance with U.S. generally accepted accounting principles requires us to make judgments, estimates and assumptions regarding uncertainties that affect the reported amounts of assets and liabilities. Significant areas of uncertainty that require judgments, estimates and assumptions include the accounting for income taxes, contingencies, valuation of derivative liabilities, asset impairment and collectability of accounts receivable. We use historical and other information that we consider to be relevant to make these judgments and estimates. However, actual results may differ from those estimates and assumptions that are used to prepare our condensed financial statements.

New Accounting Pronouncements

No new accounting pronouncements have been adopted during the six months ended June 30, 2020.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

This Report includes the certifications of our Chief Executive Officer and Principal Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified by the Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are properly recorded, processed, summarized and reported within the time periods required by the Commission’s rules and forms.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (principal executive officer and principal financial officer), of the effectiveness of the design and operation of these disclosure controls and procedures, as such term is defined in Exchange Act Rule 13a-15(e), as of June 30, 2020. Based on this evaluation, the Chief Executive Officer concluded that our disclosure controls and procedures were effective as of June 30, 2020, the end of the period covered by this Quarterly Report on Form 10-Q.

There were no changes in our internal control over financial reporting that occurred during the second quarter of 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

We are not aware of any pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various additional legal proceedings from time to time.

Item 1A. Risk Factors

Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 26, 2020. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K, except as noted below.

We are subject to risks associated with the spread of the novel strain of coronavirus, or COVID-19.

Our operations expose us to risks associated with the spread of COVID-19, which has affected the regions in which we conduct our operations. COVID-19 has broadly affected the global economy, resulted in significant travel and work restrictions in many regions and has put a significant strain on healthcare resources. COVID-19 is having, and we expect it will continue to have, an impact on our operations and an impact on the operations of CTL Amedica, the sole customer for our spine implant products, our collaborators, potential collaborators, third-party contractors and other entities, including governments, governmental agencies, with which we interact. To date, the most significant effects on our business have been reductions in sales of products to CTL Amedica which will result in reduced product revenue, delays in in discussions with potential collaborators, OEM customers, certain research and development activities and that many of our employees work remotely. In the future, the economic impacts of the COVID-19 outbreak could affect our business directly or indirectly. The effects on our product sales to CTL Amedica, research, development, manufacturing and commercialization activities, will be dependent on, among other things, the severity and duration of the COVID-19 outbreak as well as the impact of the outbreak on our third-party manufacturers, suppliers, subcontractors and customers. While the ultimate impact of COVID-19 on our business is highly uncertain, any negative impacts that materialize could materially adversely affect our operations, financial performance and stock price. Any negative impacts of COVID-19, alone or in combination with others, could exacerbate risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019. The full extent to which the COVID-19 outbreak will negatively affect our operations, financial performance and stock price will depend on future developments that are highly uncertain and cannot be predicted, including the scope and duration of the outbreak and actions taken by governmental authorities and other third parties in response to the outbreak.

Trading volume in our shares of common stock on the Nasdaq Stock Market and our recent Registered Direct common stock offerings and other sales of our Common Stock may trigger an event of default under the PPP Loan.

Our silicon nitride may not be effective in the reduction of the spread of COVID-19.

There is no guarantee that our silicon nitride will be effective in the reduction of the spread of COVID-19 by inactivating the SARS-CoV-2 virus or that we will be able to commercialize our silicon nitride for that purpose.

We may not be successful in utilizing silicon nitride in products

Although we have received positive results suggesting that it may be possible to utilize silicon nitride in products to help reduce the spread of COVID-19, there is no assurance that we will be able to integrate silicon nitride into products, or that even if we are able to do so, we will achieve positive results. Production of products for this purpose has not begun, and we may determine that it is not feasible to produce products in the desired manner, or that such products will decrease the viral disease spread on surfaces. In addition, there is significant competition from other companies trying to develop products to help treat the spread of COVID-19; many of these companies have greater resources than we do and we may not be able to successfully compete against them.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Filed Herewith	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number

10.1	Form of Share Purchase Agreement dated June 23, 2020		Form 8-K Exhibit 99.1	6/24/20	001-33624

10.2	Form of share Purchase Agreement dated June 26, 2020		Form 8-K Exhibit 99.1	6/29/20	001-33624

10.3	Promissory Note dated April 28, 2020 between SINTX Technologies, Inc. and First State Community Bank		Form 8-K Exhibit 10.1	4/30/20	001-33624

31.1	Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certificate of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

32	Certifications of the Chief Executive Officer and Principal Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101.INS	XBRL Instance Document	X

101.SCH	XBRL Taxonomy Extension Schema Document	X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	X

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	X

101.LAB	XBRL Taxonomy Extension Label Linkbase Document	X

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINTX Technologies, Inc.

Date: August 12, 2020	/s/ B. Sonny Bal
	B. Sonny Bal
	Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, B. Sonny Bal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SINTX Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2020	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, B. Sonny Bal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SINTX Technologies, Inc.;

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2020	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer and Principal Financial Officer

EX-32 4 ex32.htm

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of SINTX Technologies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The quarterly report for the quarter ended June 30, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 12, 2020	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Principal Financial Officer

EX-101.INS 5 sint-20200630.xml XBRL INSTANCE FILE 0001269026 2020-01-01 2020-06-30 0001269026 us-gaap:TrademarksMember 2019-12-31 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-12-31 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-12-31 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-12-31 0001269026 us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-12-31 0001269026 2019-12-31 0001269026 2020-06-30 0001269026 SINT:CommonStockWarrantsMember 2018-12-31 0001269026 us-gaap:CommonStockMember 2018-12-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001269026 us-gaap:RetainedEarningsMember 2018-12-31 0001269026 SINT:AssetPurchaseAgreementMember 2018-09-29 2018-10-02 0001269026 SINT:AssetPurchaseAgreementMember SINT:NoninterestBearingNoteReceivableMember 2018-09-29 2018-10-02 0001269026 SINT:AssetPurchaseAgreementMember SINT:RelatedPartyNotePayableMember 2018-09-29 2018-10-02 0001269026 2018-10-02 0001269026 2018-09-29 2018-10-02 0001269026 2018-10-31 0001269026 us-gaap:CommonStockMember 2019-12-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001269026 us-gaap:RetainedEarningsMember 2019-12-31 0001269026 SINT:CommonStockWarrantsMember 2019-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember 2019-12-31 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2019-12-31 0001269026 2019-06-06 2019-06-07 0001269026 2019-06-07 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MaximumMember 2019-01-01 2019-12-31 0001269026 SINT:ATMEquityDistributionAgreementMember 2019-01-01 2019-12-31 0001269026 2019-07-25 2019-07-26 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001269026 2019-06-30 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MaximumMember 2019-06-03 2019-06-04 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MinimumMember 2019-09-11 2019-09-12 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MaximumMember 2019-09-11 2019-09-12 0001269026 SINT:ATMEquityDistributionAgreementMember us-gaap:SubsequentEventMember 2020-09-12 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2020-06-30 0001269026 SINT:SeriesCConvertiblePreferredStockMember 2020-06-30 0001269026 SINT:SeriesCConvertiblePreferredStockMember 2019-12-31 0001269026 2019-01-01 2019-06-30 0001269026 SINT:SeriesBPreferredStocksMember 2018-12-31 0001269026 SINT:SeriesCPreferredStocksMember 2018-12-31 0001269026 SINT:SeriesBPreferredStocksMember 2019-12-31 0001269026 SINT:SeriesCPreferredStocksMember 2019-12-31 0001269026 SINT:SeriesBPreferredStocksMember 2020-01-01 2020-06-30 0001269026 SINT:SeriesBPreferredStocksMember 2019-01-01 2019-06-30 0001269026 SINT:SeriesBPreferredStocksMember 2020-06-30 0001269026 SINT:SeriesBPreferredStocksMember 2019-06-30 0001269026 SINT:SeriesCPreferredStocksMember 2020-01-01 2020-06-30 0001269026 SINT:SeriesCPreferredStocksMember 2019-01-01 2019-06-30 0001269026 SINT:SeriesCPreferredStocksMember 2020-06-30 0001269026 SINT:SeriesCPreferredStocksMember 2019-06-30 0001269026 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001269026 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001269026 us-gaap:CommonStockMember 2020-06-30 0001269026 us-gaap:CommonStockMember 2019-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001269026 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001269026 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001269026 us-gaap:RetainedEarningsMember 2020-06-30 0001269026 us-gaap:RetainedEarningsMember 2019-06-30 0001269026 2018-12-31 0001269026 2020-02-05 2020-02-06 0001269026 SINT:ATMEquityDistributionAgreementMember 2020-01-01 2020-06-30 0001269026 us-gaap:TrademarksMember 2020-06-30 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2020-06-30 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2020-06-30 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2020-06-30 0001269026 us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2020-06-30 0001269026 SINT:CommonStockWarrantsMember 2020-01-01 2020-06-30 0001269026 SINT:CommonStockWarrantsMember 2019-01-01 2019-06-30 0001269026 SINT:CommonStockWarrantsMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember 2020-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2020-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2020-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2020-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2020-06-30 0001269026 SINT:EquipmentLoanMember 2020-06-30 0001269026 SINT:EquipmentLoanMember 2020-01-01 2020-06-30 0001269026 SINT:SeriesCPreferredStockPurchaseWarrantMember 2020-02-29 0001269026 SINT:SeriesCPreferredStockPurchaseWarrantMember 2020-02-01 2020-02-29 0001269026 SINT:WarrantsExercisableMember 2020-02-01 2020-02-29 0001269026 SINT:PreferredSharesMember 2020-02-01 2020-02-29 0001269026 SINT:SeriesCConvertiblePreferredStockMember us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001269026 SINT:FollowingEighteenMonthsPaymentPeriodMember 2020-01-01 2020-06-30 0001269026 SINT:AssetPurchaseAgreementMember 2020-01-01 2020-06-30 0001269026 SINT:ATMEquityDistributionAgreementMember 2019-09-11 2019-09-12 0001269026 2020-08-10 0001269026 2020-04-01 2020-06-30 0001269026 2019-04-01 2019-06-30 0001269026 SINT:PaycheckProtectionProgramMember SINT:PPPLoanMember 2020-04-28 0001269026 SINT:PaycheckProtectionProgramMember SINT:PPPLoanMember 2020-04-27 2020-04-28 0001269026 2020-12-31 0001269026 SINT:TwoRegisteredDirectOfferingsMember 2020-01-01 2020-06-30 0001269026 SINT:SharePurchaseAgreementMember 2020-06-22 2020-06-23 0001269026 SINT:SharePurchaseAgreementMember 2020-06-23 0001269026 SINT:SharePurchaseAgreementMember 2020-06-26 0001269026 SINT:SharePurchaseAgreementMember 2020-06-25 2020-06-26 0001269026 us-gaap:SubsequentEventMember 2020-07-09 0001269026 us-gaap:SubsequentEventMember SINT:SharePurchaseAgreementMember 2020-07-16 0001269026 us-gaap:SubsequentEventMember SINT:SharePurchaseAgreementMember 2020-07-15 2020-07-16 0001269026 us-gaap:SubsequentEventMember 2020-07-08 2020-07-09 0001269026 SINT:FirstPaymentMember 2018-09-29 2018-10-02 0001269026 SINT:SecondPaymentMember 2018-09-29 2018-10-02 0001269026 SINT:SeriesBConvertiblePreferredStockMember us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001269026 SINT:HoldersOfWarrantsOneMember 2020-01-01 2020-06-30 0001269026 SINT:HoldersOfWarrantsOneMember us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001269026 SINT:HoldersOfWarrantsTwoMember 2020-01-01 2020-06-30 0001269026 SINT:HoldersOfWarrantsTwoMember us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001269026 SINT:HoldersOfWarrantsMember 2020-01-01 2020-06-30 0001269026 us-gaap:SubsequentEventMember SINT:SharePurchaseAgreementMember 2020-08-06 2020-08-07 0001269026 us-gaap:SubsequentEventMember SINT:SharePurchaseAgreementMember 2020-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft SINT:Days Sintx Technologies, Inc. 10-Q 2020-06-30 false --12-31 Non-accelerated Filer

0.01

250000000

2434009

19430913

2434009

19430913

0001269026

0.01

3112000

5100000

3100000

true false

5202000

19196000

24000

239256000

-234078000

6440000

194000

18000

255939000

238062000

-236937000

-231640000

-2859000

-2359000

-2859000

-2359000

-4028000

-730000

2020

2500000

1600000

2500000

9400000

2500000

P3Y4M24D

P2Y10M10D

P4Y9M18D

168000

2065000

Yes Yes false

-123

-9387

6427910

9440

6372000

6372350

6336577

91333

3502645

611968

64000

-64000

2434009

249

126

737

19430913

1854898

6380000 6380000

3700000

2400000

1500000

3415000

1200000

917000

1000

9400000

900000

200000

3008000 1000 3008000 1000 1600000 Q2

-2191000

-609000

-632000

533000

522000

106000

127000

639000

659000

50000

9000

11000

41000

39000

220000

1503000

1566000

220000

956000

1503000

-6328000

2037000

610000

1.62

0.00

0.18

0.36

0.00

68.51

77.50

589000

603000

392000 332000

285000

346000

15000

391000

1.50

0.10

0.0425

0.12

0.010

2021-10-01

2022-04-28

1000

5003775 611968

675

1000

1.50

1.72

1.00

2.00

2.40

1.4814

1200000

377

7447

P4Y9M18D

6000000

The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021.

3100000

8500000

6000000

2500000

300000

The amended lease has two five-year extension options.

On June 7, 2019, the lease was amended to extend the rental period through 2024

54428

29732

249000

2395000

330000

130000000

249

126

249

126

917000 6000 911000 611968

3111000

-3111000

-6380000

0.065

-0.13 -0.74 -0.68

1 for 30 reverse stock split

1700000

800000

200000

34000

800000

138889000

194444000

3100000

0.21

1300000

600000

The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization.

The Company leases office, warehouse and manufacturing space under a single operating lease.

Company's option at any time on or after the first anniversary of the expiration of the rights offering or at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the Conversion Price ($1.4814 per share).

Each Warrant is exercisable for one share of our common stock at an exercise price of $1.50 per share from the date of issuance through its expiration five years from the date of issuance. The Warrants also contain a cashless exercise provision that allows the holder to receive 70% of the common stock otherwise available under the warrant to the holder electing the cashless exercise provision. 24544308

1787000

18125000

136000

60000

310000

403000

106000

137000

1724000

2119000

4063000

20844000

533000

522000

190000

232000

41000

39000

1944000

778000

2341000

2135000

35000

9147000

24585000

191000

96000

1266000

1281000

220000

1503000

360000

383000

6000

180000

23000

2066000

3466000

1867000

1682000

12000

241000

3945000

5389000

24000

194000

239256000

255939000

-234078000

-236937000

9147000

24585000

411000

264000

204000

167000

329000

212000

163000

133000

82000

52000

41000

34000

2061000

1554000

1068000

836000

1591000

1586000

826000

615000

268000

164000

131000

105000

3920000

3304000

2025000

1556000

-3838000

-3252000

-1984000

-1522000

1000

2000

1000

2000

189000

237000

85000

115000

2037000

610000

-2128000

631000

1246000

979000

893000

-2044000

792000

-2859000

-2359000

-4028000

-730000

9491000

2358000

207000

2358000

-12350000

-4717000

-4235000

-3088000

-0.32 -2.84 -0.33 -0.78 -1.05 -2.84 -0.02 -2.53

-1.37

-5.68

-0.35

-3.31

-0.45 -3.58 -0.33 -1.46 -0.84 -2.84 -0.02 -2.53

-1.29

-6.42

-0.35

-3.99

9070655

829724

12120420

931859

11314252

829724

12120420

931859

1000 1000 500 -3337 983528 10000 -10000

1000

6454381 144415 9648000 397000 65000 1000 9583000 396000 9440 3112000 3112000 35000 -35000 3502645

34000

52000

206000 171000

2000

172000

237000

325000

9000

-76000

-79000

251000

63000

20000

5000

-79000

-19000

163000

354000

-4938000

-3333000

77000

15000

944000

695000

867000

680000

6328000

9648000

397000

5500000

4100000

3000000

8200000

406000

2000

20409000

398000

16338000

-2255000

1787000

18125000

3192000

5447000

3008000 1000 64000 2704000

1000

2000

48000

527896

354500

-2191000 -609000 -632000

2243597

0.08 -0.74 -0.68

-5050000

-2968000

-1362000

-9491000 -2358000 -2358000

-14541000

-5326000

-3720000

10000

3008000

2. Basic and Diluted Net Income (Loss) per Common Share   Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. For the three months ended June 30, 2020, there is no difference in the number of shares and net loss used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive. The Company had potentially dilutive securities, totaling approximately 1.3 million and 0.6 million as of June 30, 2020 and 2019, respectively.   Below  are basic and diluted loss per share data for the six months ended June 30, 2020, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 54%; padding-left: 10pt">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(2,859</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(2,191</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(5,050</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,491</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,491</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(12,350</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,191</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(14,541</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">9,070,655</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,243,597</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,314,252</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net income (loss) per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.32</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.13</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.45</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1.05</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.21</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.84</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net income (loss) attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1.37</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.08</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1.29</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>   Below  are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 54%; padding-left: 10pt">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(730</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(632</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(1,362</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,358</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,358</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3,088</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(632</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3,720</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">931,859</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">931,859</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.78</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.68</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(1.46</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.53</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.53</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3.31</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.68</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3.99</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>   Below  are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 54%; padding-left: 10pt">Net loss </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(2,359</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(609</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(2,968</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,358</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,358</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(4,717</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(609</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(5,326</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">829,724</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">829,724</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(2.84</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.74</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(3.58</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.84</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.84</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(5.68</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.74</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(6.42</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

0.60

15000

6100000

9600000

P2Y

915725000

9387

123

1. Organization and Summary of Significant Accounting Policies   Organization   SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company’s products are primarily sold in the United States.   Reverse Stock Split   On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed financial statements have been adjusted retroactively to reflect the reverse stock split.   Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. During the three months ended June 30, 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated.   SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 26, 2020. The results of operations for the six months ended June 30, 2020, are not necessarily indicative of the results to be expected for the year ending December 31, 2020. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019.   Use of Estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of June 30, 2020, the most significant estimates relate to inventory, long-lived and intangible assets, the liability for preferred stock and common stock warrants, and the derivative liabilities.   Liquidity and Capital Resources   The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.   For the six months ended June 30, 2020 and 2019, the Company incurred a net loss of $2.9 million and $2.4 million, respectively, and used cash in operations of $4.9 million and $3.3 million, respectively. The Company had an accumulated deficit of $237 million and $234 million as of June 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.   The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.   The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9.6 million, before considering issuance costs of approximately $0.8 million (see Note 8).   During the year ended December 31, 2019, the Company entered into an at-the-market (ATM) equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million. During the six month period ending June 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of June 30, 2020, no funding capacity is available under the ATM. (see Note 8).   On October 1, 2018, the Company sold the retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable payable over a 36-month term. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable to occur October 1, 2021. The Company expects cash flows of approximately $3.1 million for the remaining sixteen months.   Management has concluded that together with its existing capital resources and payments on the note receivable from the sale of the Spine business will be sufficient to fund operations for at least the next 12 months, or through August 2021. In the financial statements for the year ended December 31, 2019, the Company concluded substantial doubt existed for the Company to continue as a going concern. Beginning with the period ended March 31, 2020, the Company’s position changed as a result of the capital raises outlined in Note 8.   Risks Related to COVID-19 Pandemic   The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.   New Accounting Pronouncements Not Yet Adopted   The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

3. Inventories   Inventories consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">522</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">533</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>WIP</td> <td> </td> <td> </td> <td style="text-align: right">127</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Finished Goods</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">10</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">659</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">639</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of June 30, 2020, inventories totaling approximately $0.1 million and $0.5 million were classified as current and long-term, respectively. Inventories classified as current represent the carrying value of inventories as of June 30, 2020, that management estimates will be sold by June 30, 2021.

4. Intangible Assets   Intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Trademarks</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">50</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">50</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Less: accumulated amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(11</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">39</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">41</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Amortization expense for the six months ended June 30, 2020, was approximately $2.0 thousand. Amortization expense for the six months ended June 30, 2019, was approximately $2.0 thousand.

5. Fair Value Measurements   Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis   The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 72px">Level 1 -</td> <td style="text-align: justify">quoted market prices for identical assets or liabilities in active markets.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>Level 2 -</td> <td style="text-align: justify">observable prices that are based on inputs not quoted on active markets but corroborated by market data.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>Level 3 -</td> <td style="text-align: justify">unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</td></tr> </table>   The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of June 30, 2020 and December 31, 2019. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2020 and December 31, 2019 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements as of June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Description</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liability</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt">Common stock warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">1,503</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">1,503</td> <td style="width: 1%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements as of December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Description</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liability</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt">Common stock warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">220</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">220</td> <td style="width: 1%"> </td></tr> </table>   The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the six months ended June 30, 2020 and 2019 (in thousands).   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock Warrants</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">Balance as of December 31, 2018</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">(1,566</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Change in fair value</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">610</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance as of June 30, 2019</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(956</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance as of December 31, 2019</td> <td> </td> <td>$</td> <td style="text-align: right">(220</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issuance of derivatives</td> <td> </td> <td> </td> <td style="text-align: right">(6,328</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Change in fair value</td> <td> </td> <td> </td> <td style="text-align: right">2,037</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Exercise of warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">3,008</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance as of June 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1,503</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>   Common Stock Warrants   The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of June 30, 2020, and December 31, 2019, the derivative liability was calculated using the Monte Carlo Simulation valuation.   The assumptions used in estimating the common stock warrant liability as of June 30, 2020 and December 31, 2019 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Weighted-average risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">0.18%-0.36</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1.62</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted-average expected life (in years)</td> <td> </td> <td> </td> <td style="text-align: right">2.86-4.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.4</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted-average expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">68.51%-77.50</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">64</td> <td>%</td></tr> </table>   Other Financial Instruments   The Company’s recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of debt approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities   Accrued liabilities consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Payroll and related expense</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">603</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">589</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Resterilization and repackaging costs</td> <td> </td> <td> </td> <td style="text-align: right">332</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">392</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">346</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">285</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,281</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,266</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

7. Debt   Equipment Loan   In September 2019, the Company entered into a debt arrangement with a finance company to purchase equipment. The debt balance as of June 30, 2020, totaled $15 thousand. The debt incurs interest at 12%, is collateralized by the equipment and is payable in monthly payments of $1,000 (including interest) over 36 months.   PPP Loan   On April 28, 2020, the Company received funding under a Paycheck Protection Program (“PPP”) loan (the “PPP Loan”) from First State Community Bank (the “Lender”). The principal amount of the PPP Loan is $0.391 million. The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (the “SBA”). The PPP Loan has a two-year term, maturing on April 28, 2022. The term may be extended to five-years if the Lender and we agree to do so. The interest rate on the PPP Loan is 1.0% per annum. Principal and interest are payable in 18 monthly installments, beginning on November 28, 2020, until maturity with respect to any portion of the PPP Loan which is not forgiven as described below. The Company did not provide any collateral or guarantees for the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The PPP Loan provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company is permitted to prepay or partially prepay the PPP Loan at any time with no prepayment penalties. The PPP Loan may be partially or fully forgiven if the Company complies with the provisions of the CARES Act, including the use of PPP Loan proceeds for payroll costs, rent, utilities and other expenses, provided that such amounts are incurred during a 24-week period that commenced on April 28, 2020 and at least 60% of any forgiven amount has been used for covered payroll costs as defined by the CARES Act. Any forgiveness of the PPP Loan will be subject to approval by the SBA and the Lender and will require the Company to apply for such treatment in the future.   Other Debt   The Company has other debt totaling $15 thousand as of June 30, 2020 (none at December 31, 2019).

8. Equity   2020 Rights Offering   During February 2020, the Company closed on a rights offering capital raise wherein the Company’s holders of common stock, Series C Preferred Stock, and certain outstanding warrants on the date of record, obtained, at no charge, non-transferable subscription rights to purchase units (“Units”). Each Unit consisted of one share of Series C Convertible Preferred Stock (“Preferred Stock”) and 675 warrants to purchase common stock (“Warrants”). Each Unit sold for $1,000. Each share of the Preferred Stock is convertible, at the Company’s option at any time on or after the first anniversary of the expiration of the rights offering or at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the Conversion Price ($1.4814 per share). Each Warrant is exercisable for one share of our common stock at an exercise price of $1.50 per share from the date of issuance through its expiration five years from the date of issuance. The Warrants also contain a cashless exercise provision that allows the holder to receive 70% of the common stock otherwise available under the warrant to the holder electing the cashless exercise provision. The Company issued 9,440 Units, which includes 6,372,000 Warrants exercisable into shares of our common stock and preferred shares that are convertible into 6,372,350 shares of Common Stock, for gross proceeds of $9.4 million.   The Company raised $9.4 million, before consideration of issuance costs, associated with the issuance of the Units, with $3.1 million allocated to the preferred stock (with no issuance costs allocated to the preferred stock) and $5.1 million, net of issuance costs of approximately $1.2 million, allocated to the warrants. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed approximately all $1.2 million of the issuance costs.   During the six months ended June 30, 2020, Series B Convertible Preferred stockholders of the Company converted 123 shares of Series B Convertible Preferred Stock into 91,333 shares of common stock, and Series C Convertible Preferred stockholders of the Company converted 9,387 shares of Series C Convertible Preferred Stock into 6,336,577 shares of common stock.   Also, during the six months ended June 30, 2020, holders of Warrants electing to use the cashless exercise option exercised 5,003,775 warrants, which resulted in the issuance of 3,502,645 shares of common stock. During the same period of time, holders of Warrants electing to exercise warrants for cash exercised 611,968 warrants, which resulted in the issuance of 611,968 shares of common stock, and the receipt of $0.9 million of cash.   2020 Registered Direct Offerings   During June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9.6 million, before considering issuance costs of approximately $0.8 million. On June 23, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 3,700,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $1.50 per share for aggregate gross proceeds to the Company of approximately $5.5 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. Following the initial registered direct offering, on June 26, 2020, the Company entered into another Share Purchase Agreement with certain institutional purchasers pursuant to which the Company offered to the purchasers, in a registered direct offering, an aggregate of 2,400,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $1.72 per share for aggregate gross proceeds to the Company of approximately $4.1 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. See Note 14, Subsequent Events, for a description of the third and fourth registered direct offerings executed subsequent to June 30, 2020.   2019 ATM Stock Offerings   On June 4, 2019, the Company entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of its common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). On September 12, 2019, the Company entered into an amendment to the Distribution Agreement with Maxim, which increased the maximum aggregate offering price of the shares of the Company’s common stock from $1.6 million to $2.5 million. Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on the Company’s instructions. The Company has no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $2.5 million, (ii) the termination of the Distribution Agreement by either Maxim or the Company upon the provision of fifteen (15) days written notice, or (iii) September 12, 2020. The Company agrees to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the year ended December 31, 2019, the Company raised approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million, through the issuance of 527,896 shares of common stock under the Distribution Agreement with Maxim. During the six month period ending June 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million before deducting issuance fees of approximately $0.034 million. As of June 30, 2020, no funding capacity is available under the ATM.

9. Stock-Based Compensation   The Company recorded no outstanding stock option activity for the six months ended June 30, 2020. As of June 30, 2020, the Company had 377 options exercisable and outstanding with a weighted average exercisable price of approximately $7,447. The weighted average remaining contractual life was 4.8 years as of June 30, 2020. The options hold no intrinsic value. Total stock-based compensation expense included in the condensed consolidated statements of operations was $0 thousand for the six months ended June 30, 2020. There was no significant unrecognized stock-based compensation as of June 30, 2020.

10. Commitments and Contingencies   The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock options.   From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s financial position, operating results or cash flows.

11. Note Receivable   On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021. The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization. As of June 30, 2020, the net carrying value of the note receivable was approximately $2.9 million, with expected cash proceeds of $3.1 million.

12. Discontinued Operations   The Company and CTL Medical entered in an asset purchase agreement on October 1, 2018, whereby CTL Medical agreed to acquire all of the Company’s commercial spine business for total consideration of $8.5 million, which includes a $6.0 million (including interest) note receivable and CTL Medical’s assumption of the Company’s $2.5 million related party note payable to North Stadium. As a result of the closing, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. The Company has agreed to pay the cost, if any, to re-sterilize and re-package select silicon nitride spinal inventories sold to CTL Medical if the sterilization date expires prior to CTL Medical selling the inventories to a third-party customer. This agreement extends for a total of 24 months, ending on September 30, 2020. The Company estimates the sterilization and repackaging cost to approximate $0.3 million at June 30, 2020. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company in Salt Lake City. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.

13. Leases   The Company leases office, warehouse and manufacturing space under a single operating lease. On June 7, 2019, the lease was amended to extend the rental period through 2024 and reduce the amount of space leased from 54,428 square feet to 29,732 square feet. The new rent was effective January 1, 2020. The amended lease has two five-year extension options. As of June 30, 2020, the operating lease right-of-use asset totaled approximately $2.1 million and the operating lease liability totaled approximately $2.1 million. Non-cash operating lease expense during the six months ended June 30, 2020, totaled approximately $0.2 million. As of June 30, 2020, the weighted-average discount rate for the Company’s operating lease was 6.5%.   Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.   Operating lease future minimum payments together with the present values as of June 30, 2020, are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify">Years Ending December 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%">2020</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">249</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">513</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2022</td> <td> </td> <td> </td> <td style="text-align: right">528</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2023</td> <td> </td> <td> </td> <td style="text-align: right">544</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2024</td> <td> </td> <td> </td> <td style="text-align: right">561</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Total future minimum lease payments</td> <td> </td> <td> </td> <td style="text-align: right">2,395</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Less amounts representing interests</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(330</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Present value of lease liability</td> <td> </td> <td> </td> <td style="text-align: right">2,065</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Current-portion of operating lease liability</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">383</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Long-term portion operating lease liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,682</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

14. Subsequent Events   On July 9, 2020, the Company received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it has regained compliance with NASDAQ’s minimum bid price requirements for continued listing on the Nasdaq Capital Market. The letter noted that as a result of the closing bid price of the Company’s common stock having been at $1.00 per share or greater for at least ten consecutive business days, from June 22, 2020 to July 8, 2020, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.   On July 16, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 1,500,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $2.00 per share for aggregate gross proceeds to the Company of $3.0 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.   On August 7, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 3,415,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $2.40 per share for aggregate gross proceeds to the Company of $8.2 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company

Below  are basic and diluted loss per share data for the six months ended June 30, 2020, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 54%; padding-left: 10pt">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(2,859</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(2,191</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(5,050</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,491</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,491</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(12,350</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,191</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(14,541</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">9,070,655</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,243,597</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,314,252</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net income (loss) per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.32</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.13</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.45</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1.05</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.21</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.84</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net income (loss) attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1.37</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.08</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1.29</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>   Below  are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 54%; padding-left: 10pt">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(730</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(632</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(1,362</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,358</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,358</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3,088</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(632</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3,720</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">931,859</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">931,859</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.78</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.68</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(1.46</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.53</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.53</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3.31</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.68</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3.99</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>   Below  are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 54%; padding-left: 10pt">Net loss </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(2,359</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(609</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">(2,968</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,358</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,358</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(4,717</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(609</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(5,326</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">829,724</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">829,724</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(2.84</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.74</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(3.58</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.84</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.84</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(5.68</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.74</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(6.42</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

Inventories consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">522</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">533</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>WIP</td> <td> </td> <td> </td> <td style="text-align: right">127</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Finished Goods</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">10</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">659</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">639</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Trademarks</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">50</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">50</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Less: accumulated amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(11</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">39</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">41</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2020 and December 31, 2019 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements as of June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Description</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liability</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt">Common stock warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">1,503</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">1,503</td> <td style="width: 1%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements as of December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Description</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liability</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt">Common stock warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">220</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">220</td> <td style="width: 1%"> </td></tr> </table>

The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the six months ended June 30, 2020 and 2019 (in thousands).   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock Warrants</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">Balance as of December 31, 2018</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">(1,566</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Change in fair value</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">610</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance as of June 30, 2019</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(956</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance as of December 31, 2019</td> <td> </td> <td>$</td> <td style="text-align: right">(220</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issuance of derivatives</td> <td> </td> <td> </td> <td style="text-align: right">(6,328</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Change in fair value</td> <td> </td> <td> </td> <td style="text-align: right">2,037</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Exercise of warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">3,008</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance as of June 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1,503</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

The assumptions used in estimating the common stock warrant liability as of June 30, 2020 and December 31, 2019 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Weighted-average risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">0.18%-0.36</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1.62</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted-average expected life (in years)</td> <td> </td> <td> </td> <td style="text-align: right">2.86-4.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.4</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted-average expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">68.51%-77.50</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">64</td> <td>%</td></tr> </table>

Accrued liabilities consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Payroll and related expense</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">603</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">589</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Resterilization and repackaging costs</td> <td> </td> <td> </td> <td style="text-align: right">332</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">392</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">346</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">285</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,281</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,266</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Operating lease future minimum payments together with the present values as of June 30, 2020, are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify">Years Ending December 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%">2020</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">249</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">513</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2022</td> <td> </td> <td> </td> <td style="text-align: right">528</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2023</td> <td> </td> <td> </td> <td style="text-align: right">544</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2024</td> <td> </td> <td> </td> <td style="text-align: right">561</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Total future minimum lease payments</td> <td> </td> <td> </td> <td style="text-align: right">2,395</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Less amounts representing interests</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(330</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Present value of lease liability</td> <td> </td> <td> </td> <td style="text-align: right">2,065</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Current-portion of operating lease liability</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">383</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Long-term portion operating lease liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,682</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

35000 1200000 Organization   SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company’s products are primarily sold in the United States. Reverse Stock Split   On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed financial statements have been adjusted retroactively to reflect the reverse stock split.

Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. During the three months ended June 30, 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated.   SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 26, 2020. The results of operations for the six months ended June 30, 2020, are not necessarily indicative of the results to be expected for the year ending December 31, 2020. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019.

Use of Estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of June 30, 2020, the most significant estimates relate to inventory, long-lived and intangible assets, the liability for preferred stock and common stock warrants, and the derivative liabilities.

Liquidity and Capital Resources   The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.   For the six months ended June 30, 2020 and 2019, the Company incurred a net loss of $2.9 million and $2.4 million, respectively, and used cash in operations of $4.9 million and $3.3 million, respectively. The Company had an accumulated deficit of $237 million and $234 million as of June 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.   The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.   The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9.6 million, before considering issuance costs of approximately $0.8 million (see Note 8).   During the year ended December 31, 2019, the Company entered into an at-the-market (ATM) equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million. During the six month period ending June 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of June 30, 2020, no funding capacity is available under the ATM. (see Note 8).   On October 1, 2018, the Company sold the retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable payable over a 36-month term. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable to occur October 1, 2021. The Company expects cash flows of approximately $3.1 million for the remaining sixteen months.   Management has concluded that together with its existing capital resources and payments on the note receivable from the sale of the Spine business will be sufficient to fund operations for at least the next 12 months, or through August 2021. In the financial statements for the year ended December 31, 2019, the Company concluded substantial doubt existed for the Company to continue as a going concern. Beginning with the period ended March 31, 2020, the Company’s position changed as a result of the capital raises outlined in Note 8. Risks Related to COVID-19 Pandemic   The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.

New Accounting Pronouncements Not Yet Adopted   The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

513000

528000

544000

561000

EX-101.SCH 6 sint-20200630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note Receivable link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Basic and Diluted Net Income (Loss) per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Inventories - Schedule of Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Note Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Leases - Schedule of Operating Lease Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sint-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 sint-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 sint-20200630_lab.xml XBRL LABEL FILE Indefinite Lived Intangible Assets By Major Class [Axis] Trademarks [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Measurement Frequency [Axis] Fair Value, Measurements, Recurring [Member] Equity Components [Axis] Common Stock Warrants [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Common Stock [Member] Paid-In Capital [Member] Accumulated Deficit [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Asset Purchase Agreement [Member] Receivable Type [Axis] Interest Note Receivable [Member] Short-term Debt, Type [Axis] Related Party Note Payable [Member] Liability Class [Axis] Valuation Approach and Technique [Axis] Black-Scholes-Merton Valuation Model [Member] Measurement Input Type [Axis] Weighted-Average Risk-Free Interest Rate [Member] Expected Dividend Yield [Member] Weighted Average Expected Volatility [Member] Class of Stock [Axis] Series B Convertible Preferred Stock [Member] ATM Equity Distribution Agreement [Member] Range [Axis] Maximum [Member] Weighted-Average Expected Life (in years) [Member] Minimum [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Series C Convertible Preferred Stock [Member] Preferred B Stock [Member] Preferred C Stock [Member] Debt Instrument [Axis] Equipment Loan [Member] Series C Preferred Stock Purchase Warrant [Member] Warrants Exercisable [Member] Preferred Shares [Member] Scenario [Axis] Following 18-Month Payment Period [Member] PPP Loan [Member] PPP Loan [Member] Two Registered Direct Offerings [Member] Share Purchase Agreement [Member] Award Date [Axis] First Payment [Member] Second Payment [Member] Title of Individual [Axis] Holders of Warrants One [Member] Holders of Warrants Two [Member] Holders of Warrants [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] Assets Current assets: Cash and cash equivalents Account and other receivables Prepaid expenses and other current assets Inventories, net Notes receivable, current portion Total current assets Inventories, net Property and equipment, net Intangible assets, net Long-term note receivable, net of current portion Operating lease right-of-use-asset Other long-term assets Total assets Liabilities and Stockholders' Equity Current liabilities: Accounts payable Accrued liabilities Derivative liabilities Current portion of operating lease liability Current portion of debt Other current liabilities Total current liabilities Operating lease liability, net of current portion Long term debt Total liabilities Commitments and contingencies Stockholders' Equity: Convertible preferred stock, value Common stock, $0.01 par value, 250,000,000 shares authorized; 19,430,913 shares, and 2,434,009 shares issued and outstanding at June 30, 2020 and December 31, 2019. Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Convertible preferred stock, par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Product revenue Costs of revenue Gross profit Operating expenses: Research and development General and administrative Sales and marketing Total operating expenses Loss from operations Other income (expenses): Interest expense Interest income Change in fair value of derivative liabilities Offering costs Other income, net Total other income (expense), net Net loss before income taxes Provision for income taxes Net loss Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock Net loss attributable to common stockholders Net loss per share - basic and diluted Basic - net loss Basic - deemed dividend and accretion of a discount on conversion of preferred stock Basic - attributable to common stockholders Diluted - net loss Diluted - deemed dividend and accretion of a discount on conversion of preferred stock Diluted - attributable to common stockholders Weighted average common shares outstanding: Basic Diluted Balance Balance, shares Common stock issued from exercise of warrants for cash Common stock issued from exercise of warrants for cash, shares Common stock issued due to conversion of preferred stock Common stock issued due to conversion of preferred stock, shares Stock based compensation Common stock issued for cash, net of fees Common stock issued for cash, net of fees, shares Extinguishment of derivative liability upon exercise of warrant Extinguishment of derivative liability upon exercise of warrant, shares Issuance of common stock from the exercise of warrants for cash Issuance of common stock from the exercise of warrants for cash, shares Issuance of common stock from the cashless exercise of warrants Issuance of common stock from the cashless exercise of warrants, shares Preferred stock issued for cash, net of fees Preferred stock issued for cash, net of fees, shares Common stock issued on conversion of preferred stock Common stock issued on conversion of preferred stock, shares Issuance of agent warrants Beneficial conversion feature on issuance of convertible preferred stock Deemed dividend related to the issuance of preferred stock Accretion of convertible preferred stock discount Deemed dividend related to the conversion of preferred stock Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flow From Operating Activities Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation expense Amortization of right of use asset Amortization of intangible assets Non-cash interest income Change in fair value of derivative liabilities Offering Costs Bad debt expense Changes in operating assets and liabilities: Trade accounts receivable Prepaid expenses and other current assets Inventories Accounts payable and accrued liabilities Payments on operating lease liability Net cash used in operating activities EX-101.PRE 10 sint-20200630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 10, 2020
Cover [Abstract]
Entity Registrant Name	Sintx Technologies, Inc.
Entity Central Index Key	0001269026
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,544,308
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 18,125	$ 1,787
Account and other receivables	60	136
Prepaid expenses and other current assets	403	310
Inventories, net	137	106
Notes receivable, current portion	2,119	1,724
Total current assets	20,844	4,063
Inventories, net	522	533
Property and equipment, net	232	190
Intangible assets, net	39	41
Long-term note receivable, net of current portion	778	1,944
Operating lease right-of-use-asset	2,135	2,341
Other long-term assets	35	35
Total assets	24,585	9,147
Current liabilities:
Accounts payable	96	191
Accrued liabilities	1,281	1,266
Derivative liabilities	1,503	220
Current portion of operating lease liability	383	360
Current portion of debt	180	6
Other current liabilities	23	23
Total current liabilities	3,466	2,066
Operating lease liability, net of current portion	1,682	1,867
Long term debt	241	12
Total liabilities	5,389	3,945
Commitments and contingencies
Stockholders' Equity:
Common stock, $0.01 par value, 250,000,000 shares authorized; 19,430,913 shares, and 2,434,009 shares issued and outstanding at June 30, 2020 and December 31, 2019.	194	24
Additional paid-in capital	255,939	239,256
Accumulated deficit	(236,937)	(234,078)
Total stockholders' equity	19,196	5,202
Total liabilities and stockholders' equity	24,585	9,147
Series B Convertible Preferred Stock [Member]
Stockholders' Equity:
Convertible preferred stock, value
Series C Convertible Preferred Stock [Member]
Stockholders' Equity:
Convertible preferred stock, value

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Common stock, par value	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	19,430,913	2,434,009
Common stock, shares outstanding	19,430,913	2,434,009
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	126	249
Convertible preferred stock, shares outstanding	126	249
Series C Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	53	0
Convertible preferred stock, shares outstanding	53	0

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Product revenue	$ 204	$ 167	$ 411	$ 264
Costs of revenue	163	133	329	212
Gross profit	41	34	82	52
Operating expenses:
Research and development	1,068	836	2,061	1,554
General and administrative	826	615	1,591	1,586
Sales and marketing	131	105	268	164
Total operating expenses	2,025	1,556	3,920	3,304
Loss from operations	(1,984)	(1,522)	(3,838)	(3,252)
Other income (expenses):
Interest expense	(1)	(2)	(1)	(2)
Interest income	85	115	189	237
Change in fair value of derivative liabilities	(2,128)	631	2,037	610
Offering costs			(1,246)
Other income, net		48		48
Total other income (expense), net	(2,044)	792	979	893
Net loss before income taxes	(4,028)	(730)	(2,859)	(2,359)
Provision for income taxes
Net loss	(4,028)	(730)	(2,859)	(2,359)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock	(207)	(2,358)	(9,491)	(2,358)
Net loss attributable to common stockholders	$ (4,235)	$ (3,088)	$ (12,350)	$ (4,717)
Net loss per share - basic and diluted
Basic - net loss	$ (0.33)	$ (0.78)	$ (0.32)	$ (2.84)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock	(0.02)	(2.53)	(1.05)	(2.84)
Basic - attributable to common stockholders	(0.35)	(3.31)	(1.37)	(5.68)
Diluted - net loss	(0.33)	(1.46)	(0.45)	(3.58)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock	(0.02)	(2.53)	(0.84)	(2.84)
Diluted - attributable to common stockholders	$ (0.35)	$ (3.99)	$ (1.29)	$ (6.42)
Weighted average common shares outstanding:
Basic	12,120,420	931,859	9,070,655	829,724
Diluted	12,120,420	931,859	11,314,252	829,724

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred B Stock [Member]	Preferred C Stock [Member]	Common Stock [Member]	Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018
Balance, shares at Dec. 31, 2018
Common stock issued from exercise of warrants for cash				1		1
Common stock issued from exercise of warrants for cash, shares			500
Common stock issued due to conversion of preferred stock			$ 10	(10)
Common stock issued due to conversion of preferred stock, shares	(3,337)		983,528
Stock based compensation				1		1
Common stock issued for cash, net of fees			$ 1	396		397
Common stock issued for cash, net of fees, shares			144,415
Extinguishment of derivative liability upon exercise of warrant				1		1
Net loss					(2,359)	(2,359)
Balance at Jun. 30, 2019			$ 18	238,062	(231,640)	6,440
Balance, shares at Jun. 30, 2019	737		1,854,898
Balance at Dec. 31, 2019			$ 24	239,256	(234,078)	5,202
Balance, shares at Dec. 31, 2019	249		2,434,009
Common stock issued for cash, net of fees			$ 65	9,583		9,648
Common stock issued for cash, net of fees, shares			6,454,381
Extinguishment of derivative liability upon exercise of warrant				3,008		3,008
Extinguishment of derivative liability upon exercise of warrant, shares
Issuance of common stock from the exercise of warrants for cash			$ 6	911		917
Issuance of common stock from the exercise of warrants for cash, shares			611,968
Issuance of common stock from the cashless exercise of warrants			$ 35	(35)
Issuance of common stock from the cashless exercise of warrants, shares			3,502,645
Preferred stock issued for cash, net of fees				3,112		3,112
Preferred stock issued for cash, net of fees, shares		9,440
Common stock issued on conversion of preferred stock			$ 64	(64)
Common stock issued on conversion of preferred stock, shares	(123)	(9,387)	6,427,910
Issuance of agent warrants				168		168
Beneficial conversion feature on issuance of convertible preferred stock				3,111		3,111
Deemed dividend related to the issuance of preferred stock				(3,111)		(3,111)
Accretion of convertible preferred stock discount				6,380		6,380
Deemed dividend related to the conversion of preferred stock				(6,380)		(6,380)
Net loss					(2,859)	(2,859)
Balance at Jun. 30, 2020			$ 194	$ 255,939	$ (236,937)	$ 19,196
Balance, shares at Jun. 30, 2020	126	53	19,430,913

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flow From Operating Activities
Net loss	$ (2,859)	$ (2,359)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation expense	34	52
Amortization of right of use asset	206	171
Amortization of intangible assets	2	2
Non-cash interest income	(172)	(237)
Change in fair value of derivative liabilities	(2,037)	(610)
Offering Costs	325
Bad debt expense		9
Changes in operating assets and liabilities:
Trade accounts receivable	76	79
Prepaid expenses and other current assets	(251)	(63)
Inventories	(20)	(5)
Accounts payable and accrued liabilities	(79)	(19)
Payments on operating lease liability	(163)	(354)
Net cash used in operating activities	(4,938)	(3,333)
Cash Flows From Investing Activities
Purchase of property and equipment	(77)	(15)
Proceeds from notes receivable, net of imputed interest	944	695
Net cash provided by investing activities	867	680
Cash Flows From Financing Activities
Proceeds from issuance of warrant derivative liabilities	6,328
Proceeds from issuance of common stock, net of fees	9,648	397
Proceeds from issuance of preferred stock, net of fees	3,112
Proceeds from issuance of common stock in connection with exercise of warrants	917	1
Proceeds from issuance of debt	406
Principal payments on debt	(2)
Net cash provided by financing activities	20,409	398
Net increase (decrease) in cash and cash equivalents	16,338	(2,255)
Cash and cash equivalents at beginning of period	1,787	5,447
Cash and cash equivalents at end of period	18,125	3,192
Noncash Investing and Financing Activities
Reduction of derivative liability due to exercise of warrants	3,008	1
Change in par value due to conversion of preferred stock to common stock	64
Issuance of Common Stock for the Cashless Exercise of Warrants	35
Right-of-use assets and assumption of operating lease liability		2,704
Supplemental Cash Flow Information
Cash paid for interest	$ 1	$ 2

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Organization

Reverse Stock Split

Basis of Presentation

Use of Estimates

Liquidity and Capital Resources

Risks Related to COVID-19 Pandemic

New Accounting Pronouncements Not Yet Adopted

XML 18 R8.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) Per Common Share

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Basic and Diluted Net Income (Loss) Per Common Share

2. Basic and Diluted Net Income (Loss) per Common Share

Below are basic and diluted loss per share data for the six months ended June 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(2,859	)	$	(2,191	)	$	(5,050	)
Deemed dividend and accretion of a discount		(9,491	)		-			(9,491	)
Net loss attributable to common stockholders	$	(12,350	)	$	(2,191	)	$	(14,541	)

Denominator:
Number of shares used in per common share calculations:		9,070,655			2,243,597			11,314,252

Net income (loss) per common share:
Net loss	$	(0.32	)	$	(0.13	)	$	(0.45	)
Deemed dividend and accretion of a discount		(1.05	)		0.21			(0.84	)
Net income (loss) attributable to common stockholders	$	(1.37	)	$	0.08		$	(1.29	)

Below are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(730	)	$	(632	)	$	(1,362	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(3,088	)	$	(632	)	$	(3,720	)

Denominator:
Number of shares used in per common share calculations:		931,859			-			931,859

Net loss per common share:
Net loss	$	(0.78	)	$	(0.68	)	$	(1.46	)
Deemed dividend and accretion of a discount		(2.53	)		-			(2.53	)
Net loss attributable to common stockholders	$	(3.31	)	$	(0.68	)	$	(3.99	)

Below are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(2,359	)	$	(609	)	$	(2,968	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(4,717	)	$	(609	)	$	(5,326	)

Denominator:
Number of shares used in per common share calculations:		829,724			-			829,724

Net loss per common share:
Net loss	$	(2.84	)	$	(0.74	)	$	(3.58	)
Deemed dividend and accretion of a discount		(2.84	)		-			(2.84	)
Net loss attributable to common stockholders	$	(5.68	)	$	(0.74	)	$	(6.42	)

XML 19 R9.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Inventories

3. Inventories

Inventories consisted of the following (in thousands):

	June 30, 2020		December 31, 2019
Raw materials	$	522	$	533
WIP		127		106
Finished Goods		10		-
	$	659	$	639

XML 20 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2020			December 31, 2019
Trademarks	$	50		$	50
Less: accumulated amortization		(11	)		(9	)
	$	39		$	41

Amortization expense for the six months ended June 30, 2020, was approximately $2.0 thousand. Amortization expense for the six months ended June 30, 2019, was approximately $2.0 thousand.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

	Level 1 -	quoted market prices for identical assets or liabilities in active markets.

	Level 2 -	observable prices that are based on inputs not quoted on active markets but corroborated by market data.

	Level 3 -	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

	Fair Value Measurements as of June 30, 2020
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,503	$	1,503

	Fair Value Measurements as of December 31, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	220	$	220

The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the six months ended June 30, 2020 and 2019 (in thousands).

	Common Stock Warrants
Balance as of December 31, 2018	$	(1,566	)
Change in fair value		610
Balance as of June 30, 2019	$	(956	)

Balance as of December 31, 2019	$	(220	)
Issuance of derivatives		(6,328	)
Change in fair value		2,037
Exercise of warrants		3,008
Balance as of June 30, 2020	$	(1,503	)

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of June 30, 2020, and December 31, 2019, the derivative liability was calculated using the Monte Carlo Simulation valuation.

The assumptions used in estimating the common stock warrant liability as of June 30, 2020 and December 31, 2019 were as follows:

	June 30, 2020			December 31, 2019
Weighted-average risk-free interest rate		0.18%-0.36	%		1.62	%
Weighted-average expected life (in years)		2.86-4.80			3.4
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		68.51%-77.50	%		64	%

Other Financial Instruments

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

6 Months Ended

Jun. 30, 2020

Payables and Accruals [Abstract]

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2020		December 31, 2019
Payroll and related expense	$	603	$	589
Resterilization and repackaging costs		332		392
Other		346		285
	$	1,281	$	1,266

XML 23 R13.htm IDEA: XBRL DOCUMENT

Debt

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Debt

7. Debt

Equipment Loan

PPP Loan

Other Debt

The Company has other debt totaling $15 thousand as of June 30, 2020 (none at December 31, 2019).

XML 24 R14.htm IDEA: XBRL DOCUMENT

Equity

6 Months Ended

Jun. 30, 2020

Equity [Abstract]

Equity

8. Equity

2020 Rights Offering

2020 Registered Direct Offerings

2019 ATM Stock Offerings

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

XML 26 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note Receivable

6 Months Ended

Jun. 30, 2020

Receivables [Abstract]

Note Receivable

11. Note Receivable

XML 28 R18.htm IDEA: XBRL DOCUMENT

Discontinued Operations

6 Months Ended

Jun. 30, 2020

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

12. Discontinued Operations

XML 29 R19.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

13. Leases

Operating lease future minimum payments together with the present values as of June 30, 2020, are summarized as follows:

Years Ending December 31,	June 30, 2020
2020	$	249
2021		513
2022		528
2023		544
2024		561
Thereafter		-
Total future minimum lease payments		2,395
Less amounts representing interests		(330	)
Present value of lease liability		2,065

Current-portion of operating lease liability		383
Long-term portion operating lease liability	$	1,682

XML 30 R20.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

14. Subsequent Events

XML 31 R21.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Organization	Organization SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company’s products are primarily sold in the United States.
Reverse Stock Split	Reverse Stock Split On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed financial statements have been adjusted retroactively to reflect the reverse stock split.
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. During the three months ended June 30, 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 26, 2020. The results of operations for the six months ended June 30, 2020, are not necessarily indicative of the results to be expected for the year ending December 31, 2020. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of June 30, 2020, the most significant estimates relate to inventory, long-lived and intangible assets, the liability for preferred stock and common stock warrants, and the derivative liabilities.
Liquidity and Capital Resources	Liquidity and Capital Resources The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. For the six months ended June 30, 2020 and 2019, the Company incurred a net loss of $2.9 million and $2.4 million, respectively, and used cash in operations of $4.9 million and $3.3 million, respectively. The Company had an accumulated deficit of $237 million and $234 million as of June 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain. The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications. The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9.6 million, before considering issuance costs of approximately $0.8 million (see Note 8). During the year ended December 31, 2019, the Company entered into an at-the-market (ATM) equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million. During the six month period ending June 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of June 30, 2020, no funding capacity is available under the ATM. (see Note 8). On October 1, 2018, the Company sold the retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable payable over a 36-month term. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable to occur October 1, 2021. The Company expects cash flows of approximately $3.1 million for the remaining sixteen months. Management has concluded that together with its existing capital resources and payments on the note receivable from the sale of the Spine business will be sufficient to fund operations for at least the next 12 months, or through August 2021. In the financial statements for the year ended December 31, 2019, the Company concluded substantial doubt existed for the Company to continue as a going concern. Beginning with the period ended March 31, 2020, the Company’s position changed as a result of the capital raises outlined in Note 8.
Risks Related to COVID-19 Pandemic	Risks Related to COVID-19 Pandemic The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) per Common Share (Tables)

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Loss Per Share

Below are basic and diluted loss per share data for the six months ended June 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(2,859	)	$	(2,191	)	$	(5,050	)
Deemed dividend and accretion of a discount		(9,491	)		-			(9,491	)
Net loss attributable to common stockholders	$	(12,350	)	$	(2,191	)	$	(14,541	)

Denominator:
Number of shares used in per common share calculations:		9,070,655			2,243,597			11,314,252

Net income (loss) per common share:
Net loss	$	(0.32	)	$	(0.13	)	$	(0.45	)
Deemed dividend and accretion of a discount		(1.05	)		0.21			(0.84	)
Net income (loss) attributable to common stockholders	$	(1.37	)	$	0.08		$	(1.29	)

Below are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(730	)	$	(632	)	$	(1,362	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(3,088	)	$	(632	)	$	(3,720	)

Denominator:
Number of shares used in per common share calculations:		931,859			-			931,859

Net loss per common share:
Net loss	$	(0.78	)	$	(0.68	)	$	(1.46	)
Deemed dividend and accretion of a discount		(2.53	)		-			(2.53	)
Net loss attributable to common stockholders	$	(3.31	)	$	(0.68	)	$	(3.99	)

Below are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(2,359	)	$	(609	)	$	(2,968	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(4,717	)	$	(609	)	$	(5,326	)

Denominator:
Number of shares used in per common share calculations:		829,724			-			829,724

Net loss per common share:
Net loss	$	(2.84	)	$	(0.74	)	$	(3.58	)
Deemed dividend and accretion of a discount		(2.84	)		-			(2.84	)
Net loss attributable to common stockholders	$	(5.68	)	$	(0.74	)	$	(6.42	)

XML 33 R23.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Schedule of Components of Inventory

Inventories consisted of the following (in thousands):

	June 30, 2020		December 31, 2019
Raw materials	$	522	$	533
WIP		127		106
Finished Goods		10		-
	$	659	$	639

XML 34 R24.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2020			December 31, 2019
Trademarks	$	50		$	50
Less: accumulated amortization		(11	)		(9	)
	$	39		$	41

XML 35 R25.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2020 and December 31, 2019 (in thousands):

	Fair Value Measurements as of June 30, 2020
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,503	$	1,503

	Fair Value Measurements as of December 31, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	220	$	220

Schedule of Fair Value Measurement Hierarchy of Derivative Liability

The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the six months ended June 30, 2020 and 2019 (in thousands).

	Common Stock Warrants
Balance as of December 31, 2018	$	(1,566	)
Change in fair value		610
Balance as of June 30, 2019	$	(956	)

Balance as of December 31, 2019	$	(220	)
Issuance of derivatives		(6,328	)
Change in fair value		2,037
Exercise of warrants		3,008
Balance as of June 30, 2020	$	(1,503	)

Schedule of Assumptions Used in Estimating Fair Value

The assumptions used in estimating the common stock warrant liability as of June 30, 2020 and December 31, 2019 were as follows:

	June 30, 2020			December 31, 2019
Weighted-average risk-free interest rate		0.18%-0.36	%		1.62	%
Weighted-average expected life (in years)		2.86-4.80			3.4
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		68.51%-77.50	%		64	%

XML 36 R26.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2020

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2020		December 31, 2019
Payroll and related expense	$	603	$	589
Resterilization and repackaging costs		332		392
Other		346		285
	$	1,281	$	1,266

XML 37 R27.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Schedule of Operating Lease Future Minimum Payments

Operating lease future minimum payments together with the present values as of June 30, 2020, are summarized as follows:

Years Ending December 31,	June 30, 2020
2020	$	249
2021		513
2022		528
2023		544
2024		561
Thereafter		-
Total future minimum lease payments		2,395
Less amounts representing interests		(330	)
Present value of lease liability		2,065

Current-portion of operating lease liability		383
Long-term portion operating lease liability	$	1,682

XML 38 R28.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands					3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 06, 2020	Sep. 12, 2019	Jul. 26, 2019	Oct. 02, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Reverse stock split			1 for 30 reverse stock split
Net income (loss)					$ (4,028)	$ (730)	$ (2,859)	$ (2,359)
Net cash used in operating activities							(4,938)	$ (3,333)
Accumulated deficit					$ (236,937)		(236,937)		$ (234,078)
Proceeds from issuance of public offering	$ 9,400
Underwriting discounts and commissions and offering expenses payable	$ 1,200
Non interest note receivable				$ 6,000
Debt description				The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021.
Maturity date of note receivable				Oct. 01, 2021
Following 18-Month Payment Period [Member]
Proceeds from notes receivable							$ 3,100
Two Registered Direct Offerings [Member]
Number of shares issuance cost							6,100,000
Proceeds from issuance cost							$ 9,600
Stock offering expense							$ 800
ATM Equity Distribution Agreement [Member]
Proceeds from issuance of public offering		$ 2,500
Number of stock sold during period							354,500		527,896
Sale of stock value							$ 800		$ 1,700
Stock offering expense							$ 34		200
ATM Equity Distribution Agreement [Member] \| Maximum [Member]
Proceeds from issuance of public offering		$ 2,500							$ 2,500

XML 39 R29.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) Per Common Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Potentially dilutive securities	1,300,000	600,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Net loss	$ (4,028)	$ (730)	$ (2,859)	$ (2,359)
Deemed dividend and accretion of a discount, basic calculation	(207)	(2,358)	(9,491)	(2,358)
Net loss attributable to common stockholders, basic calculation	$ (4,235)	$ (3,088)	$ (12,350)	$ (4,717)
Number of shares used in per common share calculations: basic calculation	12,120,420	931,859	9,070,655	829,724
Net loss, basic calculation	$ (0.33)	$ (0.78)	$ (0.32)	$ (2.84)
Deemed dividend and accretion of a discount, basic calculation	(0.02)	(2.53)	(1.05)	(2.84)
Net income (loss) attributable to common stockholders, basic calculation	$ (0.35)	$ (3.31)	$ (1.37)	$ (5.68)
Net income (loss), effect of dilutive warrant securities		$ (632)	$ (2,191)	$ (609)
Deemed dividend and accretion of a discount, effect of dilutive warrant securities
Net loss attributable to common stockholders, effect of dilutive warrant securities		$ (632)	$ (2,191)	$ (609)
Number of shares used in per common share calculations: effect of dilutive warrant securities			2,243,597
Net income, effect of dilutive warrant securities		$ (0.68)	$ (0.13)	$ (0.74)
Deemed dividend and accretion of a discount, effect of dilutive warrant securities			0.21
Net loss attributable to common stockholders, effect of dilutive warrant securities		$ (0.68)	$ 0.08	$ (0.74)
Net income (loss), diluted calculation		$ (1,362)	$ (5,050)	$ (2,968)
Deemed dividend and accretion of a discount, diluted calculation		(2,358)	(9,491)	(2,358)
Net loss attributable to common stockholders, diluted calculation		$ (3,720)	$ (14,541)	$ (5,326)
Number of shares used in per common share calculations: diluted calculation	12,120,420	931,859	11,314,252	829,724
Net income (loss), diluted calculation	$ (0.33)	$ (1.46)	$ (0.45)	$ (3.58)
Deemed dividend and accretion of a discount, diluted calculation	(0.02)	(2.53)	(0.84)	(2.84)
Net loss attributable to common stockholders, diluted calculation	$ (0.35)	$ (3.99)	$ (1.29)	$ (6.42)

XML 41 R31.htm IDEA: XBRL DOCUMENT

Inventories (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory, current	$ 137	$ 106
Inventory, non-current	$ 522	$ 533

XML 42 R32.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Components of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 522	$ 533
WIP	127	106
Finished Goods	10
Inventory	$ 659	$ 639

XML 43 R33.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 2	$ 2

XML 44 R34.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Intangible Assets (Details) - Trademarks [Member] - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 50	$ 50
Less: accumulated amortization	(11)	(9)
Intangible assets, net	$ 39	$ 41

XML 45 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy (Details) - Fair Value, Measurements, Recurring [Member] - Common Stock Warrants [Member] - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 1,503	$ 220
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 1,503	$ 220

XML 46 R36.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) - Common Stock Warrants [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Beginning balance	$ (220)	$ (1,566)
Issuance of derivatives	(6,328)
Change in fair value	2,037	610
Exercise of warrants	3,008
Ending balance	$ (1,503)	$ (956)

XML 47 R37.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) - Common Stock Warrants [Member] - Black-Scholes-Merton Valuation Model [Member]	Jun. 30, 2020	Dec. 31, 2019
Weighted-Average Risk-Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages		1.62
Weighted-Average Risk-Free Interest Rate [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.18
Weighted-Average Risk-Free Interest Rate [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.36
Weighted-Average Expected Life (in years) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term		3 years 4 months 24 days
Weighted-Average Expected Life (in years) [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	2 years 10 months 10 days
Weighted-Average Expected Life (in years) [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	4 years 9 months 18 days
Expected Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.00	0.00
Weighted Average Expected Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages		64
Weighted Average Expected Volatility [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	68.51
Weighted Average Expected Volatility [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	77.50

XML 48 R38.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Payroll and related expense	$ 603	$ 589
Resterilization and repackaging costs	332	392
Other	346	285
Total accrued liabilities	$ 1,281	$ 1,266

XML 49 R39.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($) $ in Thousands			6 Months Ended
Debt (Details Narrative) - USD ($) $ in Thousands	Apr. 28, 2020	Oct. 02, 2018	Jun. 30, 2020	Dec. 31, 2020	Oct. 31, 2018
Debt instrument, interest rate					10.00%
Debt instrument, maturity date		Oct. 01, 2021
Other debt			$ 15
Equipment Loan [Member]
Debt principal amount			$ 15
Debt instrument, interest rate			12.00%
Debt monthly payments			$ 1
PPP Loan [Member] \| PPP Loan [Member]
Debt principal amount	$ 391
Debt instrument, interest rate	1.00%
Debt instrument term	2 years
Debt instrument, maturity date	Apr. 28, 2022
Debt forgiven amount percentage	60.00%

XML 50 R40.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands								1 Months Ended	6 Months Ended		12 Months Ended
	Aug. 07, 2020	Jul. 16, 2020	Jun. 26, 2020	Jun. 23, 2020	Feb. 06, 2020	Sep. 12, 2019	Jun. 04, 2019	Feb. 29, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Sep. 12, 2020	Jul. 09, 2020	Oct. 31, 2018
Gross proceeds of warrants exercise									$ 917	$ 1
Proceeds from issuance of units									$ 3,112
Underwriting discounts and commissions and offering expenses payable					$ 1,200
Common stock, par value									$ 0.01
Proceeds from common stock									$ 9,648	$ 397
Proceeds from public offering					$ 9,400
Debt instrument, interest rate														10.00%
Subsequent Event [Member]
Purchase price per units													$ 1.00
Two Registered Direct Offerings [Member]
Number of shares issuance cost									6,100,000
Proceeds from issuance cost									$ 9,600
Net issuance fees									800
Share Purchase Agreement [Member]
Purchase price per units			$ 1.72	$ 1.50
Number of shares of common stock			2,400,000	3,700,000
Common stock, par value			$ 0.01	$ 0.01
Proceeds from common stock			$ 4,100	$ 5,500
Share Purchase Agreement [Member] \| Subsequent Event [Member]
Purchase price per units	$ 2.40	$ 2.00
Number of shares of common stock	3,415,000	1,500,000
Common stock, par value	$ 0.01	$ 0.01
Proceeds from common stock	$ 8,200	$ 3,000
ATM Equity Distribution Agreement [Member]
Proceeds from public offering						$ 2,500
Sale of stock value									800		$ 1,700
Net issuance fees									$ 34		$ 200
Sale of stock, shares									354,500		527,896
ATM Equity Distribution Agreement [Member] \| Subsequent Event [Member]
Debt instrument, interest rate												4.25%
ATM Equity Distribution Agreement [Member] \| Maximum [Member]
Common stock offering price							$ 1,600
Proceeds from public offering						2,500					$ 2,500
ATM Equity Distribution Agreement [Member] \| Minimum [Member]
Proceeds from public offering						$ 1,600
Holders of Warrants One [Member]
Warrant exercised during period									5,003,775
Holders of Warrants Two [Member]
Warrant exercised during period									611,968
Holders of Warrants [Member]
Gross proceeds of warrants exercise									$ 900
Series C Preferred Stock Purchase Warrant [Member]
Warrants to purchase of common stock shares								675
Conversion price, description								Company's option at any time on or after the first anniversary of the expiration of the rights offering or at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the Conversion Price ($1.4814 per share).
Purchase price per units								$ 1,000
Conversion price per share								$ 1.4814
Warrants description								Each Warrant is exercisable for one share of our common stock at an exercise price of $1.50 per share from the date of issuance through its expiration five years from the date of issuance. The Warrants also contain a cashless exercise provision that allows the holder to receive 70% of the common stock otherwise available under the warrant to the holder electing the cashless exercise provision.
Warrants exercise price								$ 1.50
Number of share units issued for conversion								9,440
Gross proceeds of warrants exercise								$ 9,400
Issuance cost, total								$ 1,200
Warrants Exercisable [Member]
Number of share units issued for conversion								6,372,000
Proceeds from issuance of units								$ 5,100
Warrants issuance cost								$ 1,200
Preferred Shares [Member]
Number of share units issued for conversion								6,372,350
Proceeds from issuance of units								$ 3,100
Preferred stock issuance costs
Common Stock [Member]
Number of share units issued for conversion									6,427,910
Common Stock [Member] \| Holders of Warrants One [Member]
Number of share units issued for conversion									3,502,645
Common Stock [Member] \| Holders of Warrants Two [Member]
Number of share units issued for conversion									611,968
Common Stock [Member] \| Series B Convertible Preferred Stock [Member]
Number of share units issued for conversion									91,333
Conversion of convertible shares									123
Common Stock [Member] \| Series C Convertible Preferred Stock [Member]
Number of share units issued for conversion									6,336,577
Conversion of convertible shares									9,387

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Options outstanding \| shares
Options, exercisable \| shares	377
Weighted average exercisable price \| $ / shares	$ 7,447
Weighted average remaining contractual life	4 years 9 months 18 days
Options intrinsic value
Total stock-based compensation expense	0
Unrecognized stock-based compensation

XML 52 R42.htm IDEA: XBRL DOCUMENT

Note Receivable (Details Narrative) - USD ($) $ in Thousands		6 Months Ended
	Oct. 02, 2018	Jun. 30, 2020	Dec. 31, 2019	Oct. 31, 2018
Non interest note receivable	$ 6,000
Debt description	The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021.
Maturity date of note receivable	Oct. 01, 2021
Debt instrument, interest rate				10.00%
Imputed interest				$ 915,725
Imputed interest, description	The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization.
Notes receivable		$ 2,119	$ 1,724
Total consideration		$ 3,100
First Payment [Member]
Payments of notes receivable	$ 138,889
Second Payment [Member]
Payments of notes receivable	$ 194,444

XML 53 R43.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Details Narrative) - USD ($) $ in Thousands		6 Months Ended
	Oct. 02, 2018	Jun. 30, 2020
Total consideration		$ 3,100
Asset Purchase Agreement [Member]
Total consideration	$ 8,500
Sterilization and repackaging cost		$ 300
Asset Purchase Agreement [Member] \| Related Party Note Payable [Member]
Total consideration	2,500
Asset Purchase Agreement [Member] \| Interest Note Receivable [Member]
Total consideration	$ 6,000

XML 54 R44.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) $ in Thousands		6 Months Ended
Leases (Details Narrative) $ in Thousands	Jun. 07, 2019 ft²	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Leases [Abstract]
Lease expired, description		The Company leases office, warehouse and manufacturing space under a single operating lease.
Lease extended period, description	On June 7, 2019, the lease was amended to extend the rental period through 2024	The amended lease has two five-year extension options.
Area of lease \| ft²	54,428
Reduction of lease area \| ft²	29,732
Operating lease right-of-use asset		$ 2,135	$ 2,341
Operating lease liability		2,065
Non-cash lease expense		$ 200
Operating lease weighted-average discount rate		6.50%

XML 55 R45.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Operating Lease Future Minimum Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 249
2021	513
2022	528
2023	544
2024	561
Thereafter
Total future minimum lease payments	2,395
Less amounts representing interests	(330)
Present value of lease liability	2,065
Current-portion of operating lease liability	383	$ 360
Long-term portion operating lease liability	$ 1,682	$ 1,867

XML 56 R46.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) $ / shares in Units, $ in Thousands						6 Months Ended
	Aug. 07, 2020 USD ($) $ / shares shares	Jul. 16, 2020 USD ($) $ / shares shares	Jul. 09, 2020 Days $ / shares	Jun. 26, 2020 USD ($) $ / shares shares	Jun. 23, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares	Jun. 30, 2019 USD ($)
Common stock, par value						$ 0.01
Proceeds from common stock \| $						$ 9,648	$ 397
Share Purchase Agreement [Member]
Purchase price per share				$ 1.72	$ 1.50
Number of shares of common stock \| shares				2,400,000	3,700,000
Common stock, par value				$ 0.01	$ 0.01
Proceeds from common stock \| $				$ 4,100	$ 5,500
Subsequent Event [Member]
Purchase price per share			$ 1.00
Trading days \| Days			10
Subsequent Event [Member] \| Share Purchase Agreement [Member]
Purchase price per share	$ 2.40	$ 2.00
Number of shares of common stock \| shares	3,415,000	1,500,000
Common stock, par value	$ 0.01	$ 0.01
Proceeds from common stock \| $	$ 8,200	$ 3,000

EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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